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Chitosan is a highly promising biomaterial for regenerative medicine due to the 
combination of its advantageous biological properties and malleability. In this thesis, 
four potential applications of chitosan-based hydrogels are highlighted. The first study 
shows that chitosan films with covalently immobilized bone morphogenetic protein-2 
(BMP-2) or fibroblast growth factor-2 (FGF-2) promoted osteoblast and fibroblast 
functions to a greater extent than corresponding films with adsorbed BMP-2 or FGF-
2, due to the higher amount of growth factor retained by covalent immobilization than 
by adsorption. In the second study, BMP-2 and vascular endothelial growth factor 
(VEGF) were covalently co-immobilized on chitosan films, resulting in simultaneous 
stimulation of osteoblast and endothelial colony forming cell functions in an additive 
fashion. In the third study, hydroxyapatite (HAP) of different morphologies was 
coated on carboxymethyl chitosan (CMCS) scaffolds. Regardless of the different 
coating morphology, the HAP-coated scaffolds promoted osteoblast functions and 
osteogenic differentiation of bone marrow stem cells to a larger extent than non-
coated CMCS scaffold. Finally, mineral trioxide aggregate (MTA)-coated CMCS 
scaffolds were evaluated as dentin remineralization patch in a tooth model, and they 
induced significantly more HAP formation than non-coated CMCS scaffold. Overall, 
these studies demonstrate the feasibility and efficacy of covalent immobilization of 
growth factor for expanding the potential applications of chitosan hydrogel in bone 
and wound healing. They also highlight the benefits of using the mineralization ability 
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Diseases and injuries can impair human tissues during the course of life, resulting in 
partial or complete loss of vital tissue functions. To restore the compromised 
functions, the impaired tissues are reconstituted in tissue regeneration. However, most 
human tissues, apart from those that undergo regular replenishment (i.e. skin and 
blood), have either limited or slow regenerative capabilities. This is in contrast to 
some animals, such as planaria, salamander, and zebra fish, which can regenerate 
whole body, organs, or large part of organs. Moreover, the regenerative ability of 
human tissues decreases further with aging.  At present, transplantation and 
substitution are the common practice in cases where tissues or organs are severely 
impaired.  Transplantation, however, is constrained by scarcity of donors and immune 
rejection from the host. On the other hand, a substitute may fail to fully replace the 
functions of the original tissues or organs. In light of the limitations of the current 
therapies, there is a clear need for novel treatments as alternatives or compliments to 
the current ones (Dimitriou et al., 2011), supporting the emergence of regenerative 
medicine as a forefront field in biomedical technology.  
 
Biomaterials hold a central role in many tissue regeneration strategies since they 
provide the platforms for extracellular matrices, cells, and growth factors to interact in 
a regenerative niche (Sokolsky-Papkov et al., 2007). In the context of biomaterial 
selection, hydrogels are ideal in applications that require flexible materials to mimic 
the extracellular matrix, as opposed to those that employed the biomaterials as strong 
mechanical backbone (Tebmar et al., 2009). Due to their hydrophilic nature, 
hydrogels are highly hydrated in physiological condition, providing better oxygen and 
nutrients transport to the adjacent cells than solid materials, such as metals. Among 
the hydrogels, chitosan-based hydrogels are highly promising owing to the biological 
properties of chitosan, such as nontoxicity, biocompatibility, biodegradability, and 
antibacterial ability, in addition to the previously mentioned intrinsic hydrogel 
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characteristics. Moreover, chitosan is a versatile natural polymer that allows 
molecular alterations, such as grafting with functional groups and proteins, and 
physical treatments while retaining its structural ability to form a hydrogel (Tebmar et 
al., 2009). As such, chitosan-based hydrogels may function as promising templates 
that can be appended with regenerative agents, for example bioactive minerals, 
growth factors, and cells, as a therapeutic treatment specifically tailored for enhancing 
regeneration of a specific tissue.  
 
1.2 Objectives and scope 
The general objective of this thesis was to explore the potential applications of 
chitosan-based hydrogels in regenerative medicine, with the focus on two main 
strategies: (1) covalent immobilization of growth factors to enhance the biological 
activity of chitosan films and (2) the use of carboxymethyl chitosan (CMCS) as three-
dimensional scaffolds to induce biomineralization of calcium phosphate. Graphical 
illustration of these strategies is provided in Figure 1.1. For the first strategy, it is 
hypothesized that bone morphogenetic protein-2 (BMP-2) and fibroblast growth 
factor-2 (FGF-2) can be covalently immobilized on chitosan film by using 
carbodiimide, and the immobilized growth factor will retain its bioactivity. It is also 
hypothesized that BMP-2 and vascular endothelial growth factor (VEGF) can be 
covalently co-immobilized in controlled proportions on chitosan film using 
carbodiimide. For the second strategy, it is hypothesized that hydroxyapatite (HAP) of 
different morphologies and in different amounts can be coated on CMCS scaffolds by 
immersing the scaffolds in various mineralizing solutions. This mineralization 
capacity of CMCS can also be complimented with mineral trioxide aggregate (MTA) 
coating and the MTA-coated CMCS scaffold can be used as a remineralization patch 





Figure 1.1 Strategies for expanding the applications of chitosan-based hydrogels in 
this thesis. 
 
1) To characterize covalent immobilization of growth factors on chitosan films. 
For this purpose, bone morphogenetic protein-2 (BMP-2) and fibroblast 
growth factor-2 (FGF-2) were chosen as the model growth factors for potential 
applications in bone repair and wound healing, respectively. 
2) To compare the amount and loading efficiency of growth factor, the effects of 
the covalent immobilization on film degradation and tensile strength, growth 
factor release, and biological activities of the films with covalently 
immobilized BMP-2 or FGF-2 to those of corresponding films with adsorbed 
growth factors. 
3) To assess the potential synergism between osteogenic and angiogenic growth 
factors that were co-immobilized on chitosan films. BMP-2 and vascular 
endothelial growth factor (VEGF) were chosen for this investigation. The 
efficacy of the co-immobilized growth factors for simultaneous stimulations of 
osteogenesis and vascularization was evaluated with osteoblasts and 
endothelial colony forming cells (ECFCs).  
4) To identify and characterize calcium phosphate coatings that were formed on 
CMCS scaffolds after scaffold mineralization in various mineralizing 
solutions. The effects of the coatings characteristics on the efficacy of the 
scaffolds in promoting bone formation were then assessed with osteoblasts 
and bone marrow mesenchymal stem cells (BMSCs).  
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5) To evaluate the prospect of using CMCS scaffolds as dentin remineralization 
patches in dentistry by assessing the mineralization inducing ability of the 
scaffolds in a tooth model, which represents a more clinically relevant test 
system for dentin mineralization than conventional bulk solution system. The 
possibility of using mineral trioxide aggregate (MTA) as a bioactive dental 
material to augment the mineralization process was also investigated. 
 
1.3 Outline of the thesis 
This thesis comprised seven chapters. The motivations, objectives, and scopes of the 
thesis are described in Chapter 1. Chapter 2 presents a review of literature relevant to 
the thesis. Chapters 3 to 6 present the experimental studies conducted in this thesis. 
Conclusions of the thesis and recommendations for future studies are provided in 
Chapter 7. 
 
Chapter 3 describes a comparative study on the efficacy of covalently immobilized 
growth factors to that of adsorbed growth factors in enhancing the biological activity 
of chitosan films, with BMP-2 and FGF-2 as model growth factors. The covalent 
immobilization was facilitated using the carbodiimide chemistry, to link the carboxyl 
groups of the growth factors to the amino groups of the chitosan. It was found that the 
growth factor loading efficiency was higher for covalent immobilization than 
adsorption. The biological activity of the growth factors was not hindered by the 
immobilization procedures, as the cytokines were able to promote cell functions in a 
dose-dependent manner. In addition, substantially more growth factors were retained 
by the covalent immobilization than that by the adsorption, allowing the immobilized 
growth factors to perform their stimulatory effects for a longer period than adsorbed 
growth factors. All of these were achieved while preserving the bacterial inhibition 
property of the chitosan films.  
 
Chapter 4 presents an investigation on the prospect of simultaneous stimulation of 
osteogenesis and vascularization using chitosan films with covalently co-immobilized 
BMP-2 and VEGF. It was found that the immobilized BMP-2 promoted osteoblast 
attachment, proliferation, and differentiation. Interestingly, it also promoted 
endothelial colony forming cell (ECFC) attachment and proliferation in a comparable 
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fashion as that of the immobilized VEGF. On the other hand, the immobilized VEGF 
stimulated ECFC attachment, proliferation, differentiation, and vascularization. In 
addition, it exhibited a similar level of promotion on osteoblast attachment and 
proliferation as the immobilized BMP-2. The immobilized VEGF also stimulated 
osteoblast differentiation, although to a lesser extent than that of the immobilized 
BMP-2. The combined effects of the co-immobilized growth factors were additive. 
 
In Chapter 5, carboxymethyl chitosan (CMCS) was employed as scaffolds to support 
osteogenic cells, which were represented by osteoblasts and bone marrow 
mesenchymal stem cells (BMSCs). Due to the presence of carboxyl groups in CMCS, 
the scaffolds were readily coated with calcium phosphate of distinct morphologies 
using various mineralizing solutions. Analysis of the coatings revealed that they were 
composed of hydroxyapatite (HAP), a mineral phase commonly found in tooth and 
bone. Viability and functions of osteoblasts on the non-coated and HAP-coated 
scaffolds were evaluated. It was found that both the non-coated and coated scaffolds 
were not cytotoxic. The coated scaffolds exhibited higher enhancement of osteoblast 
functions than the non-coated scaffold. Gene expression analysis revealed that the 
coated scaffolds also stimulated osteogenic differentiation of BMSCs to a greater 
extent than the non-coated scaffold. The osteogenic effects were most apparent in the 
late stage of osteoblast differentiation, where they were observed at a similar level for 
all of the coatings regardless of the variation in coating morphology, suggesting that 
the morphology of the HAP had no significant effect on the osteogenic effects.  
 
In Chapter 6, CMCS scaffolds with and without mineral trioxide aggregate (MTA) 
coating was investigated for possible application as patches for stimulating dentin 
remineralization in tooth affected by dental caries. The investigation was carried out 
in a flow system using simulated body fluid (SBF) in a tooth model, an in vitro dental 
mineralization system constructed with extracted human tooth as its main component, 
as well as in bulk SBF solution. It was found that the non-coated CMCS scaffolds 
were capable of inducing HAP mineralization from SBF in the tooth model and bulk 
solution. Coating the scaffolds with MTA significantly enhanced the HAP formation. 
Due to the diffusion limitation imposed by the dentinal tubules, less HAP was formed 




In this study, four promising applications of chitosan films and CMCS scaffolds for 
regenerative medicine were highlighted. The work provides new prospective 
approaches to improve tissue regeneration such as, covalent co-immobilization of 
BMP-2 and VEGF on chitosan film which can be used as a wrap, osteogenic 
stimulation using in situ coated HAP on CMCS scaffold, and the use of tooth model 






2.1 Growth factor incorporation in a carrier 
Growth factors are a group of cell-secreted instructional proteins capable of directing 
a plethora of cell functions, including migration, mitosis, differentiation, and 
apoptosis (Chen et al., 2010). The action of these proteins is initiated by binding to 
cognate receptors on the target cells, triggering a cascade of signal transduction that 
ultimately lead to a specific cell response. Since the growth factors control crucial cell 
functions, they are potent regulators and inducers of tissue repair. Consequently, 
provision of exogenous growth factors, which are mainly produced as recombinant 
proteins, is viewed as a promising strategy to augment tissue regeneration. In the 
classical approach, this strategy is implemented via bolus injection of growth factor 
solutions to the intended site. However, the exogenous growth factors delivered using 
this method are prone to loss of function, requiring supraphysiological concentration 
or repetitive administrations to achieve the desired effects. Contributing factors to this 
loss of function include inaccuracy of growth factor assembly during production by 
recombinant microorganisms as well as rapid diffusion and degradation (within 30 
min) of the growth factor at the site of delivery (Cowan et al., 2005). Since a growth 
factor may be pleiotropic (influencing multiple cell types instead of only one), 
distribution of high dose of growth factors either by diffusion to the surrounding 
tissue or by systemic circulation poses risks of potentially harmful effects ranging 
from inflammation to excessive tissue growth, leading to tumor formation (Cowan et 
al., 2005; Tessmar and Gopferich, 2007). Hence, it is obvious that the growth factor 
distribution should be controlled to enable the proteins to act locally, reducing the 
side effects. This objective can be achieved by incorporating the growth factors in a 
carrier of polymeric, ceramics, or composite origins. In general, the carriers should be 
biocompatible, non-toxic, and biodegradable (Sokolsky-Papkov et al., 2007). In 
addition, the materials should support cell adhesion and proliferation, if they are also 




Growth factor incorporation in a carrier can be achieved either by growth factor 
entrapment inside the carrier or attachment of the growth factor on the surface of the 
carrier (Sokolsky-Papkov et al., 2007; Bessa et al., 2008). Growth factor entrapment 
is typically conducted simultaneously with the carrier preparation, by mixing the 
growth factor and the carrier precursor during the carrier fabrication. As such, the 
growth factor is usually subjected to harsh treatments, such as high temperature, 
sonication, and organic solvents, which may denature the cytokine, resulting in 
significant loss of bioactivity. For example, sonication can induce cavitation stress, 
which destroys the protein due to local temperature extreme (Suslick et al., 1986). 
The denatured protein, in addition to being inactive, may also cause unwanted side 
effects, such as immunogenicity and toxicity (Cleland et al., 1993; van de Weert et al., 
2000). 
 
Containment of growth factor solution in polymeric microspheres is an example of 
this entrapment method. The microspheres can be fabricated either by chemical 
crosslinking of the polymers or by solvent extraction. Solvent extraction is the more 
popular method (Freiberg and Zhu, 2004), which involves the evaporation of solvent 
from dispersed oil droplets containing the polymer. In an earlier study, polymeric 
microspheres was able to provide a sustained release of VEGF for 28 days, resulting 
in the increase of proliferation of human umbilical vein endothelial cells (King and 
Patrick, 2000). The microspheres can also be used in combination with other 
structure, such as nanofibrous scaffold to form a composite scaffold. For example, 
platelet derived growth factor containing microspheres has been embedded in 
poly(lactic acid) fibrous scaffold to stimulate the DNA synthesis of human gingival 
fibroblast in vitro (Wei et al., 2006). The incorporation of the microspheres in this 
composite scaffold has been shown to significantly reduce the initial burst release of 
the growth factor. In another study, osteogenic peptide was loaded into microparticles 
of poly(lactic-co-glycolic acid)/poly(ethylene glycol) blend and added to 
poly(propylene fumarate) porous scaffolds (Hedberg et al., 2002). The results show 
that the release kinetics of the growth factor can be controlled from the dosage of the 
growth factor as well as by altering the composition of the composite. 
 
Adsorption and covalent immobilization have been used to attach growth factors on a 
carrier. Physicochemical interactions, such as electrostatic interaction and hydrogen 
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bonding, between the growth factor and the carrier facilitate the adsorption of the 
growth factor on the carrier. Although adsorption has the advantage of intrinsic 
simplicity, sustained release of the growth factor is often not achievable due to the 
initial burst release (Bessa et al., 2008). Various materials of synthetic and natural 
origins have been used for growth factor incorporation by adsorption. For example, 
poly(lactic-co-glycolic acid) has been used to adsorb BMP-2 for repair of alveolar 
cleft in dogs (Mayer et al., 1996), rabbit ulna (Kokubo et al., 2003), and tooth defects 
in dogs (Kawamoto et al., 2003). Collagen in its various forms, such as gel, fibril, 
membrane, and sponge has been formulated for adsorption of growth factor and 
utilized for healing of bone fracture and critical size defects (Kirker-Head, 2000; 
Geiger et al., 2003). Alginate, on the other hand, has been used extensively in 
cartilage tissue engineering since it is a major constituent of cartilage tissue (Bessa et 
al., 2008). In addition of its biocompatibility, alginate is known to support the 
proliferation of chondrocytes in vitro (Park et al., 2005). Other materials, such as 
fibrin (Han et al., 2005; Hong et al., 2006), gelatin (Yamamoto et al., 2003; Takahashi 
et al., 2007), and dextran (Maire et al., 2005), have also been successfully used for 
delivering growth factor via adsorption.  
 
Chemical crosslinking is used to conjugate the functional groups of the growth factor 
and the carrier. Covalent immobilization may provide better retention of the growth 
factor on the carrier than adsorption. However, there is a risk of reducing the 
bioactivity of the growth factor after the covalent immobilization, as the bioactive 
functional groups of the cytokine may be blocked or altered during the conjugation 
procedures.  The activation of covalently immobilized growth factors, which are 
tethered to a surface, is different from that of native growth factors, which are present 
as soluble molecules (Ito, 2008). In native growth factors, the activation of cellular 
signal transduction begins with formation of binding complexes between the growth 
factors and the receptors on the surface of target cells, resulting in 
autophosphorylation of the cytoplasmic domains of the receptors. Following this 
event, the cells internalize the growth factor-receptor complexes and the receptors are 
either recycled or degraded. In the case of covalently immobilized growth factor, 
internalization and subsequent degradation of the growth factor is minimized since the 
growth factors are tightly bound to the substrate, prolonging the signal transduction 
over that by the native growth factors.  
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2.2 Chitosan as growth factor carrier for bone and wound healing 
Chitosan is a linear polysaccharide of glucosamine and N-acetyl glucosamine 
obtained from deacetylation of chitin, the second most abundant natural polymer. 
Chitin is commonly found in exoskeletons of crustaceans and cell wall of fungi (Di 
Martino et al., 2005). Chitosan exhibits various beneficial biological activities, partly 
due to its structural resemblance with glycosaminoglycans (GAGs), a group of 
polysaccharides found in extracellular matrix that play important roles in biological 
systems via interaction with biomolecules, such as, enzyme, matrix protein, and cell 
receptor. Reported advantageous properties of chitosan include its biodegradable, 
nontoxic, biocompatible, antibacterial, mucoadhesive, and wound healing properties. 
In addition, chitosan is compatible with a wide range of material modification 
processes, allowing various morphologies, such as solid film, porous scaffolds, and 
beads to be fabricated from this material. Chitosan-based materials promote 
integration by the host tissue because they evoke minimal foreign body reactions (Suh 
and Matthew, 2000). Hence, chitosan has gained considerable interests in regenerative 
medicine applications, including those associated with its implementation as a growth 
factor carrier. 
 
Chitosan has been evaluated as carriers for various growth factors involved in bone 
and wound healing, including BMP-2 (Lopez-Lacomba et al., 2006; Park et al., 2006), 
FGF-2 (Mizuno et al., 2003), and epidermal growth factor (EGF) (Alemdaroglu et al., 
2006). Chitosan films with adsorbed BMP-2 stimulated osteogenic differentiation of 
murine myoblastic cell line to osteoblasts (Lopez-Lacomba et al., 2006). 
Characterization of these films shows that the films are biodegradable, with lysozyme 
responsible for the degradation process (Abarrategi et al., 2008). A nearly complete 
desorption of BMP-2 was observed after 4 days for a chitosan film containing 1 µg 
BMP-2/cm2. To improve the growth factor retention, a high dose of BMP-2 (50-100 
µg/cm2 of film) was required, resulting in the retention of more than 80% of the 
cytokine after a week. In another study, BMP-2 was covalently immobilized on 
chitosan nanofibres prepared by electrospinning (Park et al., 2006). Succinimidyl-4-
(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), was employed to 
conjugate the amine groups of the chitosan to the sulfhydryl groups of the BMP-2. 
More than 50% of the growth factor remained immobilized to the films after 4 weeks, 
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and the films promoted attachment, mitosis, and calcium deposition of osteoblasts. In 
a study by Mizuno et al. (2003), treatment of skin wounds on diabetic mice using 
chitosan film with entrapped FGF-2 resulted in smaller wound size and higher extent 
of granulation tissue formation than those treated with the films without FGF-2, 
demonstrating the benefits of using the chitosan films as an FGF-2 carrier. As 
compared to chitosan gel without EGF, a better and faster ephithelialization was 
obtained when chitosan gel containing EGF was used in healing of second-degree 
burn wounds in rat (Alemdaroglu et al., 2006).  
 
2.3 Role of HAP in dental physiology    
Tooth and bone represent the major components of skeletal hard tissues in the human 
body. In term of chemical composition, they are composites with calcium phosphates 
and collagen as the main constituents. Calcium phosphates are the most important 
inorganic components of mineralized hard tissues like tooth and bone.  In the form of 
carbonated hydroxyapatite, it enables these tissues to function properly by conferring 
hardness and stability. Therefore, when HAP is converted into a more soluble form, 
an event known as demineralization, the functions of the tissues are impaired by 
cavitation, which may lead to mechanical failure. Pathological manifestations of 
demineralization in tooth and bone are dental caries and osteoporosis.  For bone, 
mechanical failure and bone loss may also come as a result of bone fractures and 
injuries.  
 
Mineralized tissues in tooth are found in enamel and dentin (Figure 2.1). Enamel is 
the outermost part of the tooth and is the hardest mineralized tissue in human body 
(Moioli et al., 2007). Ameoblast cells form enamel during the tooth development. In 
postnatal tissues, ameoblasts cease to exist after the enamel formation is completed; 
this is in contrast to adult somatic stem cells, which are still available in adult tissues 
for repair of damaged tissues. The second layer of the tooth is dentin, which is formed 
by odontoblasts. In the event of dentin destruction, stem cells from the dental pulp can 






Figure 2.1 Schematic diagram of a tooth. 
 
The most common ailment for tooth is tooth decay, which is reported as one of the 
most prevalent chronic diseases that affect people worldwide throughout their lifetime 
(Selwitz et al., 2007). The decay, also known as dental caries, occurs when HAP in 
tooth tissue demineralize because of acids produced by oral biofilm forming bacteria. 
If the bacterial biofilms are allowed to mature and remain on the tooth for a long 
period, cavities will be formed in the tooth. The cavities or caries lesions, if left 
untreated, will develop further, causing pain and even tooth loss. Currently, the most 
common treatment for caries is by filling the lesions with hard fillers, such as metal 
alloys and resins, after the lesions have been cleared of the biofilms. However, this 
treatment is only effective to preserve the tooth, not to regenerate it. Moreover, 
replacement of the filler is often needed due to the limited life span of the material 
(Selwitz et al., 2007; Mason and Edwards, 2009). In fact, it is estimated that two-
thirds of the 300 million restorations done by dentists each year in United States alone 
are for replacement of failed restorations (Mason and Edwards, 2009). Because of 
these limitations, alternative treatments are needed for dental caries lesions. 
Regenerative treatment is particularly promising since it can be used to bring the 
treatment forward to not only stop the development of caries but to also repair the loss 
of tooth structure. This potential is still not fully explored at present, thus it is a novel 




2.4 Mineralized CMCS as a potential material for bone grafting 
When considerable amount of bone is lost due to injuries or diseases, bone 
transplantation or grafting is required to repair the damaged bone structure. Each year, 
more than a million people worldwide require bone grafts. (Chesnutt et al., 2009; 
Giannoudis et al., 2005) As a consequence, bone grafting is the second most prevalent 
transplantation in human, after blood transfusion (Giannoudis et al., 2005). The gold 
standard of bone graft is an autograft, a graft obtained from the patient’s bone, due to 
its immunocompatibility. However, since the amount of the graft is limited and an 
extra operative surgery is needed to retrieve the autograft, it is not always a feasible 
option. Additionally, potential post-operative complications, such as bleeding and 
pain at the donor site (donor site morbidity), may occur as a result of the procedure. 
Thus, more options in bone grafts or their substitutes are necessary. Bone graft from 
another human donor or allograft is an option, but it is constrained by the same 
problems as autograft in addition to extra risks on immunocompatibility and 
transmission of disease. The issue of graft availability and supply can be improved by 
optioning for xenografts, which are from animal origin, however other problems still 
persist. Bone graft substitutes are promising replacements for human or animal 
derived bone grafts because of their intrinsic advantages in term of availability and 
versatility of handling properties. At present, various forms of bone graft substitutes 
are commercially available and have been used by dentists and orthopedic surgeons. 
Ceramics, polymers, and their composites have been used alone or in combination 
with growth factors and bone marrow in bone grafting in the forms of solid or 
injectable cements depending on the indications of the bone defects to assist the 
regeneration of the bone.  
 
In general, there are three ideal attributes required of a bone graft: osteoconductive, 
osteoinductive, and osteogenic. An osteonconductive material is a material on which 
bone-forming (osteoprogenitor) cells can attach, grow, and migrate. This type of 
material is essential for bone repair since it provides a physical template for the 
anchorage dependent cells of the osteoprogenitor to attach during the new bone 
formation (osteogenesis) while ideally the scaffold itself will degrade or being 
resorbed in concert with the bone formation. Porous materials with interconnected 
pores are particularly beneficial since they can allow penetration of the cells to the 
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scaffold interior, more area for cell attachment, and better resorption and nutrient 
transport during osteogenesis. Autograft, allograft, ceramics, bioactive glass, and 
mineral composites are known to be osteoconductive. Osteoinduction is a process that 
stimulates transformation of mesenchymal stem cells into osteoprogenitor cells and 
subsequent new bone formation by the osteoprogenitor cells. The source of 
osteoinduction can be either from signaling proteins, such as osteogenic growth 
factors, or biomaterials of the scaffold (Habibovic and de Groot, 2007). 
Ceramic/polymer composites and porous ceramics are reported to be osteoinductive, 
although, the number of positive reports are still limited. It is argued that for material-
based osteoinduction, morphology of the material plays a key role, not just the 
chemical composition. This argument is used to explain the conflicting results on 
osteoinductivity of a same material, such as calcium phosphate ceramics, by different 
research groups. Since osteogenesis is conducted by osteoprogenitor cells, only these 
cells and stem cells as their precursor have the osteogenic attribute. Currently, only 
autograft has been proven to possess all the three ideal attributes of bone graft; other 
grafts are still deemed sub-optimal as compared to autograft. Since autograft is 
restricted by its intrinsic limitations, the quest of regenerative medicine for bone with 
regard to bone graft is to discover an ideal bone graft substitutes that possess similar 
or better capacity than autograft in bone healing.  
 
Chitosan has been reported not to induce mineralization because it lacks the ability to 
chelate calcium ions. This limitation can be addressed by introducing carboxyl groups 
to chitosan, and one of the methods to do so is by carboxymethylation, with CMCS as 
the resulting product. Chitosan is osteoconductive, as it preferentially supports 
attachment of osteoblast over fibroblast (Fakhry et al., 2004). Porous chitosan 
structures are promising, since they are not only useful for osteoconduction but have 
also been suggested to be essential for osteoinduction. Porosity also plays a major role 
in the osteogenic properties of calcium phosphate. For example, porous calcium 
phosphate has been shown to be more osteoconductive and osteoinductive (Habibovic 
and de Groot, 2007) than nonporous flat calcium phosphate block. In particular, 
CMCS deposited with biomimetic calcium phosphate has the potential of functioning 




2.5 Overview of scaffold fabrication methods 
There are various techniques for polymer scaffold design and fabrication. In general, 
they can be classified into two major groups: conventional and solid free form (SFF) 
(Wiesmann and Lammers, 2009). The main difference between the two groups lies in 
the fact that computer models and precision manufacturing techniques, such as layer 
manufacturing and photolithography, are used in SFF. The precision manufacturing 
techniques allow SFF scaffolds to have a more definitive and well-controlled pore 
morphology than conventional scaffold. On the other hand, scaffolds prepared by 
conventional techniques, such as freeze-drying, gas foaming, and salt leaching, are 
generally simpler and more readily applicable because of fewer preparation steps and 
equipment needed as compared to SFF-based scaffolds. In bone tissue engineering, 
conventional techniques are often used. Formation of pores in conventional 
techniques is facilitated in various ways, such as by sublimation of ice crystals, the 
help of porogens, evaporation of solvent, and introduction of gas. 
 
Freeze-drying, also referred as freeze thawing, is a commonly used technique in 
scaffold fabrication in bone engineering because of its simplicity and usefulness; both 
scaffold formation and drying can be done in a single process in freeze-drying. The 
pores in freeze-dried sample are formed from sublimation of ice crystals from the 
frozen sample (Madihally and Matthew, 1999). Control of the pore size, to a certain 
extent, can be achieved by adjusting the cooling rate during the freezing step of the 
sample solution and the concentration of the sample. Higher cooling rate leads to 
formation of finer crystals and hence, formation of smaller pores. With increasing 
concentration of the sample, less space in the solution is left for water crystals, and 
thus smaller pores are obtained. For thick samples, uniformity of pore size is difficult 
to achieve because of the gradient in cooling rate. Therefore, for more uniform pore 
size distribution, thin sample is more beneficial. For chitosan, porous scaffolds with 
interconnected pores have been successfully fabricated using freeze-drying technique 
(Madihally and Matthew, 1999; Zhang and Zhang, 2001). Because of the high water 
absorption characteristic of chitosan hydrogel, which in turn results in the formation 
of many ice crystals in the chitosan solution during the freezing step, many 





ENHANCING BIOACTIVITY OF CHITOSAN FILM FOR 
OSTEOGENESIS AND WOUND HEALING USING 
COVALENTLY IMMOBILIZED BMP-2 OR FGF-2 
 
3.1 Introduction 
In this study, chitosan film was used as a substrate for covalent immobilization of 
either BMP-2 or FGF-2 via carbodiimide chemistry. BMP-2 and FGF-2 are prominent 
cytokines in osteogenesis (Zhang et al., 2010) and wound healing (Berscht et al., 
1994), respectively. It can be envisioned that if the BMP-2 and FGF-2 functionalized 
chitosan films are both bioactive and antibacterial, they can be used in the proximity 
of the injured site to enhance osteogenesis and wound healing, for example, as a wrap 
for fractured bones or a wound dressing. In earlier studies, it was shown that chitosan 
film with adsorbed BMP-2 (Lopez-Lacomba et al., 2006) and nanofibrous chitosan 
membrane with BMP-2 conjugated using SMCC can potentially enhance 
osteointegration and bone formation (Park et al., 2006). Chitosan has demonstrated 
protective effects on FGF-2 (Masuoka et al., 2005) and when used together with 
gelatin microspheres containing FGF-2, chitosan scaffold accelerated closure of 
diabetic ulcer wound in aged mice (Park et al., 2009). Genipin was previously 
employed to covalently immobilize FGF-2 on a chitosan film (Lefler and Ghanem, 
2009). However, this approach was unsuccessful as the FGF-2 release profile from 
this film was not different from that of a corresponding film with adsorbed FGF-2.  
 
This study aimed to enhance the bioactivity of chitosan films by covalent 
immobilization of either BMP-2 or FGF-2, and compare the growth factor loading 
efficiency, growth factor retention, and bioactivity of the films with those of 
corresponding films with adsorbed growth factor. To our knowledge, only one study 
(Park et al., 2006) comparing the covalent immobilization and adsorption of BMP-2 
on chitosan is currently available despite the above-mentioned advantages of covalent 
immobilization of growth factor. Moreover, that study was limited only to BMP-2, 
raising the question of whether the findings were also applicable to other growth 
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factors, such as FGF-2. The attachment, proliferation, and differentiation of MC3T3 
osteoblasts on the BMP-2 functionalized films were assayed to evaluate the 
bioactivity of the adsorbed and covalently immobilized BMP-2. As for the films with 
adsorbed and covalently immobilized FGF-2, attachment, proliferation, and collagen 
synthesis of 3T3 fibroblasts were investigated. Bacterial adhesion on the growth 
factor functionalized films was also assessed with Staphylococcus aureus (S. aureus), 
which represents a clinically relevant bacterial strain responsible for biomaterial 
infection (Harraghy et al., 2006; Mack et al., 2004).  
 
3.2 Experimental section 
3.2.1 BMP-2 and FGF-2 loading on chitosan films 
All chemicals were from Merck (Darmstadt, Germany) unless otherwise stated. 
Chitosan with 85% degree of deacetylation and viscosity average molecular weight of 
1 × 105 (as per the manufacturer’s specification) was purchased from Koyo Chemical 
(Osaka, Japan). Chitosan 3% w/v solution was obtained by dissolving 3 g of chitosan 
powder overnight in 100 ml of 0.2 M acetic acid. Pristine chitosan film was prepared 
by drying 2 ml of the chitosan solution in a polystyrene dish with diameter of 5 cm 
overnight at 60ºC. The film was then immersed in 1 M NaOH for 5 min, detached 
from the dish, washed three times with water, freeze dried for 6 h, and cut into discs 
(6.35 mm diameter and 70 µm thick) and rectangles (2.5 cm × 5 mm × 70 µm), as 
shown in Figure 3.1a and 3.1b. The film thickness was obtained from scanning 
electron microscopy (SEM), which will be described in detail in Section 3.2.3.  
 
 
Figure 3.1 Pristine chitosan film as (a) disc, (b) rectangle, and (c) wrap. SEM image 




The discs were used in growth factor release and cell culture studies, whereas the 
rectangles were utilized for degradation and tensile tests. Each disc was sterilized by 
immersion in 70% ethanol for 1 h and washed three times with sterile phosphate 
buffered saline (PBS, pH 7.4) in aseptic condition before being loaded with growth 
factors. In this study, the term ‘loaded’ refers to adsorption as well as covalent 
immobilization. Six growth factor loaded films were prepared, as listed in Table 3.1. 
Adsorption of growth factor was carried out by immersing a pristine disc in 100 µl of 
loading solution containing 2 µg/ml of BMP-2 or FGF-2 in PBS for 1 h, followed by 
a rinsing with 200 µl PBS for ~ 1 min to remove non-adsorbed growth factor. For the 
covalent immobilization of the growth factor, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) hydrochloride was used to form covalent bonds between 
carboxyl groups of the growth factor and amine groups of the chitosan. N-
hydroxysuccinimide (NHS) is often added to the reaction to stabilize O-acylisolurea 
intermediate formed in the initial reaction between EDC and the growth factor. Due to 
its simple, inexpensive, and effective conjugation procedures, EDC has been widely 
used for conjugating biomolecules to polymers (Masters, 2011), e.g. fibronectin to 
chitosan films (Custodio et al., 2010), heparin to chitosan scaffolds (Gumusderelioglu 
and Aday, 2011), BMP-2 to collagen (Yamachika et al., 2009) and poly(ethylene 
terephthalate) (Zouani et al., 2010), vascular endothelial growth factor and 
angiopoietin-1 to collagen scaffolds (Chiu and Rasidic, 2010), and epidermal growth 
factor to poly(caprolactone) scaffolds (Choi et al., 2008). Figure 3.2 depicts the 
covalent immobilization of growth factor on chitosan film involving EDC and NHS. 
The process starts with the reaction between EDC and carboxyl groups of the growth 
factor to form an O-acylisolurea intermediate. This intermediate is unstable in 
aqueous solution and will react with NHS to form a more stable NHS ester, which can 
be readily displaced by the amine groups of the chitosan film, forming the covalent 





Figure 3.2 Schematic diagram of covalent immobilization of growth factor on 
chitosan film using EDC and NHS.  
 
In the present study, EDC (Sigma-Aldrich, St. Louis, MO, USA) was first added to 
the pristine chitosan film before the film was subjected to the loading solution to 
minimize covalent conjugation among the growth factor molecules, which possess 
both the amine and carboxyl groups. The procedure involved placing a pristine disc in 
100 µl of PBS containing 4 mg/ml EDC and 6 mg/ml NHS for 10 min followed by 
dabbing of the disc on a sterile filter paper to remove the excess solution. The disc 
was then immersed in 100 µl of the loading solution for 1 h followed by 8 cycles of 5-
min washing with 200 µl PBS to remove unconjugated growth factor. The loading 
solution contained either 0.66 µg/ml or 2 µg/ml of BMP-2 (United States Biological, 
Swampscott, MA, USA) and FGF-2 (R&D Systems, Minneapolis, MN, USA), 
respectively. As for the rectangles, the growth factor adsorption and covalent 
conjugation was carried out in a similar fashion as that for the discs but with 400 µl of 






Table 3.1. List of BMP-2 and FGF-2 loaded chitosan films 
Film Growth 
factor 
Concentration of growth 
factor in the loading 
solution (µg/ml) 






CAB BMP-2 2 Adsorption   39.4 ± 5.3 24.5 ± 5.2 
CCB1 BMP-2 0.66 Covalent conjugation   37.3 ± 4.3 66.8 ± 6.1 
CCB2 BMP-2 2 Covalent conjugation 103.2 ± 7.1 61.2 ± 7.8 
CAF FGF-2 2 Adsorption   89.3 ± 5.2 52.4 ± 3.2 
CCF1 FGF-2 0.66 Covalent conjugation   32.5 ± 4.4 46.5 ± 6.3 
CCF2 FGF-2 2 Covalent conjugation   84.8 ± 6.7 49.2 ± 4.5 





3.2.2 Quantification of loaded growth factor 
Quantikine Enzyme-Linked Immunosorbent Assay (ELISA) kits for FGF-2 and BMP-
2 were purchased from R&D Systems (Minneapolis, MN, USA). The total amount of 
growth factor (covalently bound or adsorbed) on a film was calculated from the 
difference in the growth factor concentration in the loading and washing solutions (as 
measured using the Quantikine ELISA kits) before and after the loading procedures. 
For the CAB and CAF films, an alternative procedure to quantify the adsorbed growth 
factor via a growth factor desorption method was also employed. In this method, each 
disc was placed in 100 µl of PBS containing 1 M HCl (pH 4) for 1 h to desorb the 
growth factor (Chiu and Rasidic, 2010). The resulting solution was neutralized using 
1 M NaOH before the growth factor was quantified using the ELISA kits. As shown 
later in Section 3.3.1, the results of the two methods were in agreement with each 
other. However, the difference method was preferred over the desorption method 
since the standard deviation of the former was smaller than the latter. For the films 
with covalently immobilized growth factor, the amount of growth factor that was 
adsorbed rather than covalently bound was determined using the desorption method. 
The amount of covalently immobilized growth factor was then obtained by 
subtracting the adsorbed growth factor from the total amount of loaded growth factor. 
 
3.2.3 SEM of the chitosan films  
SEM was employed to determine the film thickness and to analyze the surface 
morphology of pristine and growth factor functionalized chitosan films. For film 
thickness measurement, cross section of the chitosan films was prepared by snap-
freezing of the films in liquid nitrogen. The cross section and surface of the films was 
then coated with platinum before imaging at 15 kV using a JSM 5600LV scanning 
electron microscope (JEOL, Tokyo, Japan).  
 
3.2.4 Degradation of films with covalently immobilized growth factor  
Each piece of pre-weighed dry rectangles (2.5 cm × 5 mm × 70 µm) of the pristine 
films and films with covalently immobilized growth factor was immersed in 5 ml of 
degradation solution (10 µg/ml lysozyme in PBS) in a 15 ml tube maintained at 37ºC 
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in a water bath shaker operating at 100 rpm.  The degradation solution was refreshed 
daily to maintain the activity of the lysozyme and the test was carried out for 3 weeks. 
The specimen was then collected, washed three times with water, dried in a 60ºC oven 
overnight, and weighed. The percent of remaining specimen weight was calculated as 
the measure of film degradation.  
 
3.2.5 Tensile properties of films with covalently immobilized growth factor 
In these tensile tests, two parameters were evaluated: ultimate tensile strength (UTS) 
and Young’s modulus (YM). UTS is a measure of the maximum force per unit of 
cross-sectional area that a film can withstand before it breaks. YM corresponds to the 
elasticity of a film, with a decreasing value indicating an increase in elasticity. An 
Instron 5544 Universal Testing Machine (Norwood, MA, USA) equipped with Merlin 
mechanical testing software was used to measure the UTS and YM of the pristine film 
and films with covalently bound growth factor (2.5 cm × 5 mm × 70 µm) in hydrated 
and dry states before and after degradation by lysozyme. For the tensile tests of the 
dry degraded films, the films obtained after the degradation study was used directly 
without further treatment. Hydrated films were prepared by immersing dry films for 1 
h in PBS.  The tests were carried out using a gauge length of 1.5 cm and a constant 
tensile strain rate of 10 mm/min.  
 
3.2.6 Growth factor release from the growth factor loaded films 
The release kinetics of BMP-2 and FGF-2 from the growth factor loaded discs was 
investigated by placing each disc in 100 µl of PBS as the release solution in a 1.5 ml 
capped tube at 37ºC without stirring. At designated time points, the release solution 
was collected and replaced with fresh PBS. The amount of growth factor in the 
release solution was then measured using the ELISA kits. 
 
3.2.7 Bacterial adhesion on the growth factor loaded films 
The number of adherent S. aureus (ATCC 25923, Manassas, VA, USA) on the growth 
factor loaded films was evaluated using a method described in a previous study (Shi 
et al., 2009). For this assay, squares of cellulose acetate (Goodfellow, Cambridge, 
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UK), the pristine chitosan, and growth factor loaded chitosan films (1 cm × 1 cm × 70 
µm) were tested. Since cellulose acetate is not antibacterial (Lala et al., 2007; Son et 
al., 2004), it was used as a positive control for the pristine chitosan film. S. aureus 
was cultured overnight in tryptic soy broth at 37ºC with agitation and an aliquot of the 
bacterial suspension was subsequently cultured for 8 h. The bacteria were collected 
using centrifugation at 2700 rpm for 10 min, washed with PBS, and resuspended in 
PBS at a concentration of 106 cells/ml. Each substrate was then placed in a 24-well 
plate and incubated in 1 ml of the bacterial suspension for 6 h at 37ºC. This 
incubation period was chosen as it represents the crucial early period of bacterial 
adhesion (Poelstra et al., 2002). After the incubation, the substrates were gently rinsed 
with PBS and placed in tryptic soy broth. Bacteria on the substrates were dislodged by 
ultrasonication for 2 min followed by vortexing. The bacterial suspension was diluted 
using 10-fold serial dilution and the number of bacteria was quantified using the 
spread plate method with the results reported as number of viable bacteria/cm2. 
 
3.2.8 Bioactivity assays of the growth factor loaded films 
Cell culture reagents were from Invitrogen (Carlsbad, CA, USA). MC3T3-E1 
subclone 14 mouse osteoblasts, and 3T3 fibroblasts were obtained from ATCC 
(Manassas, VA, USA). The bioactivity assays were carried out with osteoblasts for 
the BMP-2 loaded discs and fibroblasts for the FGF-2 loaded discs, with the pristine 
disc as the control. Before cell seeding, the pristine discs and the discs with covalently 
bound growth factor were equilibrated in growth medium (Dulbecco’s modified eagle 
medium with 10% fetal bovine serum, 100 mg/ml streptomycin, and 100 U/ml 
penicillin) for 1 h. For the discs with adsorbed growth factor (CAB and CAF), the 
equilibration was integrated with the growth factor adsorption by using growth 
medium instead of PBS as the medium for the growth factor and the rinsing solution. 
This procedure was necessary since the growth factor would be released into the 
medium if the equilibration was carried out after the adsorption of the growth factor. 
For the cell attachment assay, each disc was placed on a 96-well plate, covered with 
100 µl of growth medium containing either 20,000 osteoblasts or fibroblasts, and 
incubated for 4 h at 37ºC in a 5% CO2 incubator to allow the cells to attach to the 
film. The film was then carefully washed using 200 µl PBS before the attached cells 
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were dislodged using 100 µl of trypsin and counted using a hemocytometer. As will 
be shown later in Section 3.3.6, the number of attached cells was different for each 
type of the film when an identical number of cells was used in the seeding. For the 
proliferation study, the number of cells seeded on each type of films was adjusted to 
obtain ~5,000 of attached osteoblasts or fibroblasts per disc after a 4-hour attachment 
period. Except for the different number of cells used in the cell seeding, the seeding 
procedures, cell attachment period, and post-attachment rinsing for the proliferation 
study were identical to those described above for the cell attachment study. Following 
the rinsing, each cell-seeded disc was transferred to a 24-well plate and incubated in 1 
ml of the growth medium and maintained at 37ºC in the incubator with subsequent 
medium change every 2 days. At 2, 4, 6, and 8 days post-seeding, the discs were 
washed once with PBS and the cells were detached and counted as previously 
described.  
 
For the osteoblast differentiation study, a differentiation medium comprising the 
growth medium supplemented with 50 µg/ml ascorbic acid and 10 mM β-
glycerophosphate was used. Similar osteoblast seeding and maintenance procedures 
as those for the proliferation study were followed. The osteoblast differentiation was 
assessed in terms of alkaline phosphatase (ALP) activity and calcium deposition. 
After 1, 2, and 3 weeks post-seeding, the films were collected and carefully rinsed 
three times with PBS. The osteoblasts were lysed using 200 µl of lysis buffer (10 mM 
Tris, 1 mM MgCl2, and 0.02% Triton X in water) per disc and the lysate was collected 
after ultrasonication and centrifugation at 10,000 rpm for 5 min each. Protein content 
in 25 µl of the lysate was determined using bicinchoninic acid (BCA) protein assay 
kit (Pierce Biotechnology, Rockford, IL, USA). ALP activity of 50 µl of the lysate 
was measured as the production rate of p-nitrophenol (p-NP) from a p-nitrophenyl 
phosphate (p-NPP) substrate when the reaction was carried out at 37ºC for 90 min. 
The reaction was stopped using 1 M NaOH and the absorbance at 405 nm was 
measured with a spectrophotometer. The concentration of p-NP was obtained using a 
standard calibration curve. The ALP activity was reported as amount of produced p-
NP (in µM) per mg of protein per min. For the calcium assay, the mixture of 50 µl of 
the lysate and the post-lysis film was dissolved overnight in 65% nitric acid. The 
solution was diluted and filtered before its calcium content was measured using an 
Agilent Technologies 7500 inductively coupled plasma mass spectrometer (ICP-MS, 
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Agilent Technologies, CA, USA) with the results reported as µg of deposited calcium 
per mg of protein.   
 
The effects of the pristine chitosan and FGF-2 loaded films on the collagen synthesis 
were investigated by comparing the amount of collagen synthesized by fibroblasts on 
the tissue culture polystyrene (TCPS, Corning, USA) and the respective film. 
Approximately 5,000 fibroblasts were seeded on TCPS, pristine chitosan film, and 
FGF-2 loaded films in a 96-well plate followed by the cell maintenance using the 
method previously described in the proliferation assay. After 4 days, the medium was 
replaced with growth medium supplemented with 50 µg/ml ascorbic acid and the 
discs were incubated for 4 h in the 5% CO2 incubator (Chen et al., 2002). The 
medium was then supplemented with 20 µg/ml of proline and the incubation was 
continued for 20 h. After the medium was removed, the intracellular collagen 
concentration was determined using Sirius red staining (Choudhary et al., 2007). For 
this purpose, the fibroblasts were lysed using the method described for osteoblasts in 
the ALP activity assay and 50 µl of the lysate was transferred to a 96-well plate. The 
plate was then placed in the 5% CO2 incubator for 16 h before being transferred to a 
37ºC dry incubator with desiccant and left to dry overnight. Each well was rinsed 
three times (1 min each) using 200 µl of ultrapure water. To each well, 100 µl of 
0.1% w/v Sirius red dye in 1.3% picric acid (Sigma-Aldrich, St. Louis, MO, USA) 
was added. The plate was incubated at room temperature for 1 h to allow the dye to 
bind to the collagen. Each well was then rinsed five times with 200 µl of 0.1 M 
hydrochloric acid (10 s per rinsing) to remove unbound dye. The bound dye was then 
released using 200 µl of 0.1 M NaOH followed by mixing for 5 min. The released dye 
was transferred to a new 96-well plate and its absorbance at 540 nm was determined 
using a Tecan GENios (Männedorf, Switzerland) microplate reader. The amount of 
collagen was determined using a corresponding standard curve. The results are 
reported with and without normalization with respect to the protein content of the 
lysate, which was measured using the BCA protein assay kit. 
3.2.9 Statistical analysis 
Each assay was carried out in three replicates (n = 3) with the data presented as mean 
± standard deviation. All data was analyzed using one-way ANOVA with Tukey’s 
post hoc test (P < 0.05). 
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3.3 Results and discussion 
3.3.1 BMP-2 and FGF-2 loading on the chitosan films 
The amount of loaded growth factor and the growth factor loading efficiency on the 
chitosan films are presented in Table 3.1. The amount of the adsorbed or covalently 
immobilized growth factor in Table 3.1 is normalized by the dry weight of the film. 
The growth factor loading efficiency is the percentage of the initial amount of growth 
factor in the loading solution that was adsorbed or covalently immobilized on a film. 
From the desorption method, the amount of adsorbed growth factor for the CAB and 
CAF films was 35.4 ± 9.3 and 81.3 ± 9.1 ng/mg chitosan, respectively. This amount is 
similar to that obtained from the difference method (Table 3.1), suggesting that the 
two methods were reliable. However, the desorption method resulted in a higher 
standard deviation than the difference method. Hence the difference method was 
preferred. Using the desorption method, it was found that the quantity of adsorbed 
growth factor on the films with covalently bound growth factor was insignificant 
since it contributed less than 1% to the total amount of loaded growth factor. This 
indicates that the eight cycles of washing was adequate in removing adsorbed growth 
factor from these films.  
 
The growth factor loading efficiency of adsorbed FGF-2 for the CAF film was 
significantly higher than that of BMP-2 for the CAB film, suggesting that FGF-2 has 
a stronger affinity for the pristine chitosan film than BMP-2. Based on the 
manufacturer’s specifications, BMP-2 is a 26 kDa homodimeric protein with two 115 
amino acid chains while FGF-2 contains 146 amino acids with a molecular weight of 
17 kDa. The two growth factors were used on the same weight basis of 2 µg/ml; 
hence there was a higher concentration of FGF-2 molecules than BMP-2 during the 
adsorption procedure. The higher amount of adsorbed FGF-2 on the chitosan film 
than BMP-2 may be due to the differences in the growth factor size/structure or the 
concentration effect. The difference in the growth factor loading efficiency between 
the films with adsorbed growth factors (comparing CAB with CAF) is larger than 
those of the corresponding films with covalently bonded growth factors (comparing 
CCB1 with CCF1, and CCB2 with CCF2). This may indicate the robustness of the 
covalent conjugation since the growth factor loading efficiency using this method is 
less dependent on the type of growth factor than the adsorption method. As 
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demonstrated by the CCB2 and CAB films, the amount of covalently immobilized 
BMP-2 was significantly higher than that of adsorbed BMP-2 when an identical 
loading solution was used. With this difference, it would be difficult to compare the 
activity of the adsorbed and covalently immobilized BMP-2 in the assay of osteoblast 
functions. To address this issue, the CCB1 film was prepared to have approximately 
the same amount of BMP-2 as the CAB film. With the FGF-2 loaded films, an 
opposite result was obtained. When an identical loading solution was used, the 
amount of FGF-2 covalently immobilized on the CCF2 film was similar to that 
adsorbed on the CAF film. The CCF1 film was formulated to contain one-third of the 
FGF-2 of the CCF2 film to investigate the effect of the amount of immobilized FGF-2 
on the fibroblast functions. For the films with covalently immobilized BMP-2 (CCB1 
and CCB2) and the FGF-2 (CCF1 and CCF2), the amount of growth factor in the 
loading solution did not have a significant effect on the growth factor loading 
efficiency.  
 
It is well known that supraphysiological concentration is needed for exogenous 
soluble growth factor to elicit tissue repair, leading to various limitations including 
high cost of treatment (Axelrad et al., 2007). Since a carrier can retain the growth 
factor and protect it from degradation (Ito, 2008), growth factor incorporation into a 
carrier is a promising solution to reduce the amount of required growth factor. In this 
context, a carrier with a high growth factor loading efficiency is desirable. However, 
comparative data on the growth factor loading efficiency of covalently conjugated and 
adsorbed growth factor on a chitosan substrate is not widely available. In an earlier 
study, BMP-2 was covalently immobilized on a electrospun chitosan nanofibers using 
SMCC (Park et al., 2006). However, no information on the growth factor loading 
efficiency was provided. In another study, BMP-2 was covalently conjugated to 
poly(ε-caprolactone) using sulfo-SMCC (Zhang et al., 2010). It was found that the 
growth factor loading efficiency was higher than that of adsorption. In the present 
study, a similar advantage of covalent conjugation over adsorption was also observed 
when EDC was used to covalently conjugate BMP-2 to chitosan. However, this 
advantage was not applicable to FGF-2 since the growth factor loading efficiency of 




3.3.2 Degradation of films with covalently immobilized growth factor 
Figure 3.3 presents the degradation profiles of the pristine chitosan film, pristine 
chitosan film treated with EDC without the growth factors, and the chitosan films 
with covalently immobilized growth factor, showing that the films are biodegradable. 
The films with covalently immobilized growth factor degraded at a slower rate than 
the pristine film. Since pristine chitosan film treated with EDC without the growth 
factors has a similar degradation rate as that of the untreated pristine film, the lower 
degradation rate of the films with the covalently bound growth factor can be attributed 
to the covalent conjugation of the growth factors. Figure 3.1d shows that the pristine 
chitosan film was non-porous. With this non-porous structure, most of the adsorption 
and covalent conjugation should occur on the surface of the films, although a small 
fraction of the growth factor may diffuse into the films when the films were immersed 
in the loading solutions. During the covalent conjugation of the growth factor, amide 
bonds formed between the growth factor and the chitosan may have strengthened the 
film and reduced its degradation rate. No significant difference was observed among 
the films with covalently immobilized growth factor, indicating that the type of 
growth factor (BMP-2 or FGF-2) had no major effect on the film degradation. 
Chitosan degradation in the human body occurs primarily via enzymatic hydrolysis of 
the glycosidic bonds of chitosan by lysozyme with the degradation rate being 
inversely proportional to the degree of deacetylation (Shi et al., 2006; Varum et al., 
1997). Lysozyme is a ubiquitous enzyme that can be found in various human body 
fluids, such as serum, saliva and tears (Hankiewicz and Swierczek, 1974). The 
lysozyme concentration (10 µg/ml) chosen in this study represents that commonly 
found in human serum (Jiang et al., 2010). The hexameric binding site of lysozyme is 
responsible for its interaction with chitosan (Pangburn et al., 1982). It was found that 
hexasaccharides sequences of chitosan containing 3-4 or more acetylated units are the 
main contributor for the early stage of the degradation (Nordtveit et al., 1996). Since 
chitosan with 85% degree of deacetylation was used in this study, a relatively low 
degradation rate was expected due to the limited number of acetylated groups. This 
was indeed the case with more than 85% of the initial weight of the pristine film and 
92% of the films with covalently immobilized growth factor remaining after 3 weeks 
in the degradation solution. Moreover, the degradation rate is slower as the number of 
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acetylated sequences decreases during the enzymatic hydrolysis (Freier et al., 2005), 
as reflected after one week in Figure 3.3.  
 
 
Figure 3.3 Degradation profile of the pristine chitosan (CH), chitosan film treated 
with EDC without the growth factors (CHE), and the films with covalently 
immobilized growth factor in PBS containing 10 µg/ml lysozyme. 
 
3.3.3 Tensile properties of films with covalently immobilized growth factor 
Figure 3.4 shows the UTS and YM of the pristine film and the films with covalently 
immobilized growth factor before and after 3 weeks in the degradation solution.  
Significant decrease in UTS was observed for the pristine chitosan after 2 and 3 
weeks in the degradation solution (Figure 3.4a). On the contrary, there was no 
significant decrease for the films with covalently immobilized growth factor after 3 
weeks. From Figure 3.3, the weight loss of the pristine film after 2 and 3 weeks was 
~11% and 13%, respectively; while only ~8% weight of the films with covalently 
immobilized growth factor was lost after 3 weeks. The results suggest that the 
decrease in UTS was caused by the film degradation. However, the decrease was only 
apparent after more than ~11% weight of the film was lost. Figure 3.4b shows that the 
YM for all films decreased approximately by half after 1 week and reached a plateau 
afterwards. For hydrated pristine chitosan films, UTS and YM were 1.1 ± 0.4 MPa 
and 4.5 ± 0.9 MPa, respectively, which represents a five and ten-fold decrease as 
compared to those for the dry film. Nevertheless, after hydration, the films still 





Figure 3.4 Ultimate tensile strength (a) and Young’s modulus (b) of the dry pristine 
chitosan (CH) film and the films with covalently immobilized growth factor. * 
denotes significant difference (P < 0.05) from the value before degradation. 
 
3.3.4 Retention of adsorbed and covalently immobilized growth factor 
The growth factor release profiles of the films with adsorbed and covalently 
immobilized growth factor in PBS are shown in Figure 3.5. As will be shown in 
Section 3.3.6, the ALP activity and calcium deposition were monitored for 3 weeks. 
Therefore, the same duration was selected for the growth factor release assay to 
enable correlation between the growth factor release with the bioactivity of the films. 
Release of the adsorbed growth factors occurred predominantly in the first day, with 
more than 50% BMP-2 and 40% FGF-2 released in this period. This burst release is 
typical for carriers with adsorbed growth factor because of the relatively weak 
interactions between the growth factors and the carriers (Silva et al., 2009). Due to the 
fast release, only ~16% and ~21% of BMP-2 and FGF-2 remained adsorbed on their 
respective films after 3 weeks, rendering the films ineffective for growth factor 
retention. In the physiological environment, such release may lead to the loss of the 
growth factor through blood circulation. For in vitro cell culture, the loss occurs via 
medium change. Abarrategi et al. (2008) showed that adsorbed BMP-2 retention on 
chitosan films could be improved by using high BMP-2 loading (50-100 µg/cm2 
film), which yielded 80-85% BMP-2 retention after one week. However, this 
approach may be cost-prohibitive due to the high cost of the BMP-2. For the films 
with covalently immobilized growth factor, ~78% and ~82% of the BMP-2 and FGF-
2 remained immobilized on the films after 3 weeks, showing that the films had a 
significantly better growth factor retention than that of the corresponding films with 
adsorbed growth factor. The retention of the growth factor may also minimize the 
negative effects of uncontrolled release of growth factors, such as heterotopic bone 
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formation (formation of bone in non-bony site), tissue swelling, and growth factor 
degradation (Haidar et al., 2009a; Haidar et al., 2009b). Since the films were not 
treated with lysozyme, growth factor release from the films was not caused by film 
degradation and may be attributed to hydrolysis of the covalent bond between the 
growth factor and chitosan. 
 
 
Figure 3.5 Cumulative growth factor release from the chitosan films with adsorbed 
and covalently immobilized BMP-2 (a) and FGF-2 (b) in PBS. 
 
3.3.5 Bacterial adhesion on growth factor functionalized films 
Bacterial infection remains a key problem for implanted biomaterials since it poses a 
serious health risk to the patients and may lead to implant failure (Katsikogianni et al., 
2004; Bratskaya et al., 2007). Bacterial adhesion, if left uncontrolled, can become the 
starting point for biofilm formation, leading to severe bacterial infection (Poelstra et 
al., 2002; Katsikogianni et al., 2004). Thus, one potential strategy to address this issue 
is to use a material that inhibits bacterial adhesion (Bratskaya et al., 2007), which 
occurs in the crucial early period of biomaterial implantation. Figure 3.6 shows the 
number of adherent S. aureus on the cellulose acetate film, pristine chitosan film, 
growth factor loaded chitosan films. The number of adherent bacteria on the pristine 
chitosan and chitosan films with adsorbed and covalently immobilized growth factor 
was six-fold lower than that on the cellulose acetate film. No significant difference in 
bacterial adhesion was observed among the chitosan films. The results show that the 
pristine chitosan film inhibited bacterial adhesion, and the adsorbed and covalently 





Figure 3.6 Number of viable S. aureus on the cellulose acetate (CA) film, pristine 
chitosan film (CH), and the growth factor loaded films. * denotes significant 
difference (P < 0.05) to the CA film. 
 
3.3.6 Bioactivity of the BMP-2 loaded films 
Figure 3.7a shows the number of osteoblasts on the pristine and BMP-2 loaded 
chitosan films (CAB, CCB1, and CCB2) after a 4-hour attachment period. 
Significantly more osteoblasts attached on the BMP-2 loaded films than on the 
pristine film. The number of adherent osteoblasts on the CCB1 film was higher than 
that on the CAB film even though the initial amount of loaded BMP-2 on the two 
films is similar (Table 3.1). Since no medium replacement was carried out during the 
osteoblast attachment assay, the cumulative amount of BMP-2 in the medium and on 
the films for the CAB and CCB1 films were similar throughout the attachment period. 
By measuring the amount of BMP-2 in the medium after the 4-hour attachment 
period, it was found that ~23% and 0.6% of the BMP-2 was released from the CAB 
and CCB1 films, respectively. Since higher osteoblast attachment was observed on 
the CCB1 film than on the CAB film, it can be concluded that osteoblast attachment 
was affected more by the actual amount of growth factor on the film surface than the 
initial amount of loaded growth factor. This is supported by the work of Shiels et al. 
(2012), who reported an increase of osteoblast attachment when BMP-2 was coated 
on HAP disks. Comparing the CCB1 and CCB2 films, more osteoblasts were found 
on the CCB2 film, which had a higher amount of loaded BMP-2 (Table 3.1). 
Previously, Park et al. (2006) also documented the promotion of osteoblast attachment 
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in a dose-dependent manner by BMP-2 that was covalently immobilized to a chitosan 
membrane using SMCC. On the other hand, they reported similar osteoblast 
attachment on the membrane with covalently immobilized BMP-2 as that on a 
corresponding membrane with adsorbed BMP-2. This finding is different from what 
we observed in our study. The difference may arise from the use of a shorter cell 
attachment period of 2 h as compared to the 4 h used in our study. In a more recent 
study, Custódio et al. (2010) observed that osteoblast attachment on chitosan film 
with covalently immobilized fibronectin was significantly higher that of 
corresponding film with adsorbed fibronectin. The finding was attributed to the higher 
resistance of the covalently immobilized fibronectin to desorption than that of its 
adsorbed counterpart, supporting the results of our study. Figure 3.7b shows the 
osteoblast proliferation profiles over an 8-day period. The profile for the pristine film 
shows that the film supports osteoblast proliferation (Gumusderelioglu and Aday, 
2011; Jones, et al., 2009). The osteoblast proliferation was higher for the BMP-2 
loaded films than the pristine film, with the highest proliferation rate observed for the 
CCB2 film, followed by the CCB1 and CAB films. The results clearly demonstrate 
that both adsorbed and covalently immobilized BMP-2 promoted osteoblast 
proliferation on the chitosan films. Since the BMP-2 release was significantly higher 
from the CAB film than from the CCB1 film (Figure 3.5), the amount of BMP-2 lost 
through the medium change was higher for the former. This may account for the 
lower osteoblast proliferation on the CAB film. The results also indicate that an 
increased amount of covalently conjugated BMP-2 was advantageous for osteoblast 
proliferation (comparing the CCB2 film with the CCB1 film).  
 
 
Figure 3.7 Number of osteoblasts on the pristine chitosan (CH) and the BMP-2 
loaded films from the attachment (a) and proliferation (b) assays. * and # denote 
significant difference (P < 0.05) compared to the CH and CAB films, respectively. + 
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indicates that the value for the CCB2 film differs significantly (P < 0.05) from that for 
the CCB1 film. 
 
The ALP activity and calcium deposition results are shown in Figure 3.8. The ALP 
activity for the CAB film was higher than the pristine film only on the first week 
(Figure 3.8a). On the contrary, the ALP activity for the CCB1 film was higher than 
that for the pristine film throughout the 3-week period, and higher than that for the 
CAB film on the second and third week. Since ALP is an early marker for osteoblast 
differentiation (Christenson, 1997), these results suggest that both adsorbed and 
covalently immobilized BMP-2 stimulated the early stage of osteoblast 
differentiation. However, the stimulation was more sustainable for the covalently 
immobilized BMP-2 than adsorbed BMP-2 due to the retention of the growth factor 
on the film by covalent conjugation. As for the CCB2 film, the ALP activity was 
consistently higher than the other films throughout the 3-week period. Figure 3.8b 
shows that the calcium deposition was significantly higher for the BMP-2 loaded 
films than that for the pristine film after 2 and 3 weeks. The calcium content on the 
CCB1 film was higher than that on the CAB film only on the third week, whereas the 
CCB2 film exhibited higher calcium deposition than the CCB1 and CAB films after 
the first week. Since calcium deposition marks the late stage of osteoblast 
differentiation (Christenson, 1997), these findings indicate that the BMP-2 loaded 
films also promote the late stage osteoblast differentiation, with the degree of 
promotion proportional to the amount of covalently immobilized BMP-2.  
 
 
Figure 3.8 ALP activity (a) and calcium deposition (b) results for osteoblasts cultured 
on the pristine chitosan (CH) and the BMP-2 loaded films. * and # denote significant 
difference (P < 0.05) compared to the CH and CAB films, respectively. + indicates 
that the value for the CCB2 film differs significantly from that for the CCB1 film. 
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3.3.7 Bioactivity of the FGF-2 loaded films 
The number of attached fibroblasts on the pristine and FGF-2 loaded films after 4 h is 
shown in Figure 3.9a. Significantly more fibroblasts attached on FGF-2 loaded films 
than on the pristine film. Since fibroblasts can express FGF receptors (Moscatelli and 
Devesly, 1990), these cells can interact with FGF-2, resulting in the enhancement of 
cell attachment. Previously, this effect was also documented for fibroblasts cultured 
on tissue culture polystyrene and treated with FGF-2 (Richard et al., 1995). The 
number of adherent fibroblasts was similar between the CAF and CCF1 films, while 
that for the CCF2 film was higher than both the CAF and CCF1 films. From Table 
3.1, it can be seen that the CAF film contained three times more FGF-2 than the 
CCF1 film. Based on FGF-2 content in the medium after the cell attachment assay, 
~81% and ~99% of FGF-2 remained on the films with adsorbed and covalently 
immobilized FGF-2, respectively. The amount of adsorbed FGF-2 on the CAF film 
(in weight of FGF-2/mg film) was ~2.2 times more than its covalently immobilized 
counterpart on the CCF1 film. Since the efficacy of the CCF1 film in promoting 
fibroblast attachment is similar to the CAF film despite this discrepancy in the amount 
of loaded FGF-2, the covalently immobilized FGF-2 may be more bioactive than the 
adsorbed FGF-2. It is well documented that conformation change of FGF-2 can affect 
its bioactivity. The most common example of this is the observed increase in FGF-2 
activity when it is bound to components of extracellular matrix, such as heparin 
(Benoit and Anseth, 2005). Recently, some studies have demonstrated that this 
increase can also be obtained for FGF-2 that was covalently immobilized to a 
polyamide surface (Nur-E-Kamal et al., 2008; Delgado-Rivera et al., 2009). In view 
of these recent studies, conformational change may also be responsible for the 
bioactivity enhancement of the covalently immobilized FGF-2 in our study. Figure 
3.9b shows the fibroblast proliferation profiles for the pristine and FGF-2 loaded 
films up to 8 days. The 8-day period was selected since a clear trend of the 
proliferation can be established within this time frame. It is apparent from this Figure 
that the FGF-2 loaded films stimulate fibroblast proliferation better than the pristine 
film, with the highest stimulation exhibited by the CCF2 film, followed by the CCF1 
and CAF films. The bioactivity enhancement by the covalently immobilized FGF-2 
on the CCF1 film and the loss of adsorbed FGF-2 from the CAB film during medium 
change may account for the higher extent of fibroblast proliferation on the former 
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than that on latter. As demonstrated by the CCF2 film, a higher level of stimulation on 




Figure 3.9 Number of fibroblasts on the pristine chitosan (CH) and the FGF-2 loaded 
films from the attachment (a) and proliferation (b) assays. * and # denote significant 
difference (P < 0.05) compared to the CH and CAF films, respectively. + indicates 
that the value for the CCF2 film differs significantly (P < 0.05) from that for the 
CCF1 film. 
 
In the early phase of wound repair, fibroblasts play a crucial role in synthesizing and 
remodeling new extracellular matrix, with collagen as the main component of this 
matrix. Figure 3.10 shows the amount of collagen produced by fibroblasts on the 
pristine and FGF-2 loaded films after 4 and 8 days normalized by total protein content 
(a) and the total collagen content (b). No significant difference in the normalized 
collagen content was observed between the pristine and FGF-2 loaded films in Figure 
3.10a. However, the total collagen content was higher for the FGF-2 loaded films than 
that for the pristine film after 4 and 8 days (Figure 3.10b).  Among the FGF-2 loaded 
films, the total collagen content was highest for the CCF2 film after 8 days. These 
results suggest that the adsorbed and covalently immobilized FGF-2 did not increase 
the collagen production of fibroblasts on a per cell basis. Instead, the higher collagen 
production for the FGF-2 loaded films was a consequence of the increase in fibroblast 






Figure 3.10 Amount of collagen synthesized by fibroblasts on the pristine chitosan 
(CH) and the FGF-2 loaded films normalized by total protein content (a) and the total 
collagen content (b). * and # denote significant difference (P < 0.05) compared to the 
CH and CAF films, respectively. + indicates that the value for the CCF2 film differs 
significantly (P < 0.05) from that for the CCF1 film. 
 
3.4 Summary 
Covalent immobilization of BMP-2 and FGF-2 on chitosan films using carbodiimide 
was successfully carried out in this study. The amount of immobilized growth factor 
can be readily controlled by adjusting the growth factor concentration in the loading 
solution. For covalent immobilization of BMP-2, the growth factor loading efficiency 
of ~64% was 2.6 times higher than what could be achieved via adsorption. On the 
other hand, the growth factor loading efficiency for the FGF-2 was ~50% for both 
covalent immobilization and adsorption. After 3 weeks in PBS, the films with 
covalently bound BMP-2 and FGF-2 retained ~80% of the initial amount of loaded 
growth factor, while films with adsorbed growth factor retained ~20% or less of the 
growth factors over the same period. Since the adsorbed BMP-2 is more readily lost, 
the films with covalently immobilized BMP-2 stimulated osteoblast attachment, 
proliferation, and differentiation to a greater extent than the films with adsorbed 
BMP-2. Covalently immobilized FGF-2 appears to have higher bioactivity than 
adsorbed FGF-2 in the stimulation of fibroblast attachment, proliferation, and 
collagen synthesis. The advantages of the covalently immobilized growth factors were 
achieved while preserving the bacterial inhibition property of the chitosan films. With 
the demonstrated bioactivity towards osteoblasts and fibroblasts, the chitosan films 
with covalently conjugated growth factor have potential applications in promoting 
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The coordination between osteogenesis and vascularization is essential in bone repair 
(Carano and Filvaroff, 2003; Kanczler and Oreffo, 2008). Hence, a therapy that 
simultaneously promotes the two processes is highly desired. One implementation of 
this dual osteogenic and angiogenic strategy involves the administration of BMP-2 
and VEGF through a carrier that limits the release of the growth factors and protects 
them from degradation and inactivation (Young et al., 2009; Kempen et al., 2009; Ito, 
2004). In general, application of this strategy in animal studies resulted in better bone 
repair than a corresponding approach targeting only either one of the two processes 
(Patel et al., 2008; Kanczler et al., 2010). Peng et al. (2005) found that administration 
of sFlt1, a specific VEGF antagonist, significantly inhibited BMP-2 activity, 
highlighting the importance of angiogenesis in bone formation. It has been shown in 
an animal model that the increase in angiogenesis resulted in accelerated cartilage 
resorption, leading to an increased mineralized bone formation (Kempen et al., 2009). 
However, the mechanisms behind this enhancement, especially those regarding the 
roles of BMP-2 and VEGF and their interactions in the dual growth factors setup, are 
poorly understood at present. This has been complicated by the fact that both BMP-2 
and VEGF are pleiotropic, affecting multiple functions of different types of cells 
(Patel et al., 2008). Besides the need for better understanding of the mechanism, an 
improvement in the dual BMP-2 and VEGF delivery system is also desirable. In the 
past, the growth factors are incorporated via entrapment or adsorption. Although these 
methods provide higher growth factor retention than bolus injection, a better retention 
of the growth factors (Luginbuehl et al., 2004) can be achieved via covalent 




In the present study, BMP-2 and VEGF were covalently co-immobilized on chitosan 
films. Osteoblasts and ECFCs were used to evaluate the osteogenic and angiogenic 
activity of the growth factor functionalized films. Osteoblasts were chosen since they 
are responsible for osteogenesis in physiological condition. ECFCs represent a 
subpopulation of endothelial progenitor cells that can directly be incorporated into 
neovasculatures in vivo (as opposed to contributing via a paracrine mechanism). 
These cells exhibit high proliferative capacity and are capable of differentiating into 
endothelial and smooth muscle cells, which form the endothelium and its underlying 
tunica media, respectively (Critser et al., 2011; Hur et al., 2004; Timmermans et al., 
2009; Fioretta et al., 2012). Hence, ECFCs are widely considered as promising but 
relatively unexplored cells for angiogenic applications. 
 
The underlying hypothesis of this study was that the covalently co-immobilized BMP-
2 and VEGF could enhance osteogenesis and vascularization to a greater extent than 
either of the immobilized growth factor alone. The objective of this study was to 
evaluate the prospect of using co-immobilized BMP-2 and VEGF on chitosan films to 
simultaneously promote osteogenesis and vascularization. In addition, the interactions 
between the immobilized BMP-2 and VEGF as well as those between the growth 
factors and osteoblasts and ECFCs were also investigated. 
 
4.2 Experimental section 
4.2.1 Covalent co-immobilization of BMP-2 and VEGF on chitosan films 
The chemicals were obtained from Merck (Darmstadt, Germany). Chitosan films 
were prepared and cut into discs as previously described in Section 3.2.1. Prior to 
growth factor immobilization, each disc was sterilized in 70% ethanol for 1 h and 
washed three times with sterile PBS. The concentration of BMP-2 and VEGF in the 
loading solution (with PBS as the diluent) is listed in Table 4.1. Each disc was placed 
in 100 µL of PBS containing 4 mg/ml EDC and 6 mg/ml NHS for 10 min, dabbed 
once on sterile filter paper to remove excess solution, immersed for 1 h in 100 µL of 
loading solution, and washed with 8 cycles of 200 µL PBS for 5 min each to remove 




4.2.2 Quantification of immobilized growth factors and growth factor release  
The quantification of immobilized growth factors was carried out using Quantikine 
ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the procedures 
described earlier in Section 3.2.2. To evaluate the amount of BMP-2 and VEGF 
released with time, each growth factor functionalized disc was incubated in 100 µL of 
PBS at 37ºC without stirring in capped 1.5 ml tubes. After 1 and 3 weeks, the amount 
of BMP-2 and VEGF in the PBS was measured using the ELISA kits. 
 
4.2.3 Cell attachment assay 
In this and subsequent cell culture assays, reagents from Invitrogen (Carlsbad, CA, 
USA) were used. MC3T3-E1 osteoblasts and ECFCs were obtained from ATCC 
(Manassas, VA, USA) and Lonza (Walkersville, MD, USA), respectively. The 
osteoblasts were expanded in Dulbecco’s modified eagle medium with 10% fetal 
bovine serum, 100 mg/ml streptomycin, and 100 U/ml penicillin. To prepare the 
growth medium for ECFCs, basal  medium  (EBM-2) was first supplemented with 
EGM-2 SingleQuots (Lonza, Walkersville, MD, USA). In this process, the VEGF 
component of the SingleQuots was excluded to ensure that VEGF effects in the 
subsequent experiments could be attributed to the covalently immobilized VEGF 
rather than soluble VEGF. The medium formulation was completed with the addition 
of ECFC Serum Supplement. In this attachment assay and the subsequent cell culture 
studies, osteoblasts from passage 5-10 and ECFCs from passage 4-10 were used. 
Sterile discs of pristine and growth factor functionalized chitosan film was 
equilibrated in 100 µL of growth medium for 1 h prior to cell seeding in a 96-well 
plate. The equilibration medium was then aspirated, and ~4,000 osteoblasts or ECFCs 
in 100 µL growth medium were seeded on each disc, followed by a 4-hour attachment 
period at 37ºC in a 5% CO2 incubator. Following the cell attachment, the discs were 
carefully rinsed with 200 µL PBS to remove unattached cells and divided into two 
groups for viable cell staining by acetomethoxy derivate of calcein (calcein AM) and 
counting using hemocytometer. To initiate the calcein staining, the discs were 
incubated in 100 µL PBS containing 2 µM calcein AM for 30 min before the cells 
were examined under a Leica DMLM fluorescent microscope (Wetzlar, Germany). 
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For the cell counting, the cells on the discs were detached using 100 µL of trypsin and 
counted using hemocytometer. 
 
4.2.4 Cell proliferation assay 
The pristine and growth factor functionalized discs were first equilibrated in growth 
medium as described above for the cell attachment assay. After the medium was 
removed, osteoblasts or ECFCs were seeded in 100 µL of their respective medium. 
As will be shown later in Section 4.3.2, the number of attached cells on each type of 
the discs differs when medium with identical number of cells is used. Hence, the 
number of the cells in the seeding medium for this proliferation assay was adjusted to 
obtain ~1,000 attached osteoblasts or ECFCs per disc after 4 h. The discs were then 
rinsed once with 200 µL PBS and placed in a new 96-well plate. Medium (200 µL) 
was added to each well and the plate was maintained at 37ºC in the CO2 incubator for 
8 days with medium change every 2 days. Cell proliferation was assessed via cell 
counting as described above. 
 
4.2.5 ALP activity and calcium deposition assays 
ALP activity and calcium deposition assays were performed to evaluate osteoblast 
differentiation on the pristine and growth factor functionalized films. Similar cell 
seeding and attachment procedures as those of the proliferation study were followed 
and a differentiation medium comprising growth medium supplemented with 50 
µg/ml ascorbic acid and 10 mM β-glycerophosphate was used. At 1, 2, and 3 weeks 
post-seeding, the medium was removed and the discs were gently washed with PBS. 
The cells were lysed using 200 µL of CellLytic M reagent and the lysate was 
collected after ultrasonication and centrifugation at 10,000 rpm for 5 min each. ALP 
activity and the calcium content of the lysate were then determined using the 







Table 4.1 Growth factor loading and release from BMP-2 and VEGF functionalized films 
 Concentration of loading 
solution (µg/ml) 
 Amount of immobilized 
growth factor (ng/mg)# 
 
 
Cumulative growth factor 
release (%)* 
Film BMP-2 VEGF BMP-2 VEGF  1 week 3 weeks 
C1 1 0.9    64.3 ± 6.7   67.8 ± 7.5  13.5 ± 0.4 15.3 ± 0.3 
C2 4.5 0.9  265.5 ± 17.2   63.9 ± 5.1  14.1 ± 0.6 15.7 ± 0.4 
C3 1 4    59.3 ± 6.2 263.9 ± 21.4  13.8 ± 0.4 15.5 ± 0.6 
CCB2 2 -  121.6 ± 6.3          -  13.2 ± 0.6 15.5 ± 0.5 
CCV2 - 1.8  - 129.2 ± 8.1  13.6 ± 0.4 15.9 ± 0.6 






4.2.6 Gene expression of endothelial markers 
Quantitative PCR of CD31 and vWF was used to investigate the effects of the 
immobilized growth factors on endothelial differentiation of the ECFCs. Primers for 
the genes are listed in Table 4.2. Prior to RNA extraction, the cells were seeded and 
maintained as for the cell proliferation assay. After 1 week, the discs with attached 
cells were carefully rinsed with PBS before total RNA of the cells was isolated and 
quantified using RNeasy® Mini Kit (Qiagen, Valencia, CA, USA) and Quant-iT™ 
RNA Assay Kit (Invitrogen, Carlsbad, CA, USA), respectively. Reverse transcription 
and quantitative PCR were conducted using iScript™ One-Step RT-PCR Kit with 
SBYR® Green in an iCycler iQ5 PCR Detection System (Bio-Rad Laboratories, 
Hercules, CA, USA) according to the manufacturer’s instructions. In each PCR 
reaction, 300 nM each of forward and reverse primer and 10 ng of total RNA were 
used. To facilitate comparisons across different samples, the data was normalized 
with that of pristine chitosan film. With β–actin as the housekeeping gene, relative 
gene expression was calculated as follows (Pfaffl, 2001): 
 
Relative expression = (EP-target)ΔCt-target / (EP-BA)ΔCt-BA  
Where, EP is the Pfaffl efficiency (amplification efficiency + 1); target refers to either 
CD31 or vWF; ΔCt is the difference in cycle threshold of CD31 or vWF from that of 
the pristine chitosan film; and BA denotes β-actin.  
 
Table 4.2 Primers for quantitative PCR analysis of CD31 and vWF expression by 
ECFCs 
Genea Accession number Primer sequence (5'-3') 
BA NM_001101.3 Sense AGCCTCGCCTTTGCCGATCC 
  Antisense CATGCCCACCATCACGCCCT 
CD31 NM_000442.4 Sense AGTCCTGCTGACCCTTCTGCTCT 
  Antisense GCTTGACGTGAGAGGTGGTGCT 
vWF NM_000552.3 Sense GCTGTTTGACGGGGAGGTGAATGT 
  Antisense CCAGACCACGGAGAGGGCTTTG 




4.2.7 Immunostaining of CD31 and vWF of ECFCs 
Immunostaining was conducted to analyze the CD31 and vWF expression by ECFCs 
at the protein level after 1 week of cell culture. Discs with seeded cells were rinsed 3 
times with PBS followed by fixation of the cells using 100 µL of 3.7% 
paraformaldehyde in PBS for 15 min at room temperature. Each disc was then washed 
twice with PBS and the cells were permeabilized using 0.5% Triton-X for 5 min. To 
block non-specific staining, the disc was immersed for 30 min in PBS containing 3% 
bovine serum albumin (BSA). After the blocking buffer was removed, the disc was 
incubated for 1 h in FITC-conjugated human CD31 antibody (Invitrogen, Carlsbad, 
CA, USA) or vWF (Novus Biologicals, Littleton, CO, USA) diluted in PBS 
containing 1% BSA. The disc was then rinsed 3 times with PBS before the cell nuclei 
were stained using a DAPI containing mounting medium (Fluoroshield with DAPI, 
Sigma-Aldrich, St. Louis, MO, USA). The fluorescence intensity of the antibody and 
DAPI were then examined using Nikon Eclipse Ti microscope with C-HGFIE 
Intensilight fiber illuminator (Nikon Instruments, Melville, NY, USA). 
 
4.2.8 Matrigel assay 
The effects of the immobilized growth factors on tubule formation by ECFCs were 
investigated using a Matrigel assay. To prepare for the assay, growth factor reduced 
Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was first thawed at 0ºC on ice. 
The thawed Matrigel (50 µL) was immediately transferred to pre-cooled 96-well plate 
and incubated at 37ºC for 30 min to allow the Matrigel to solidify. ECFCs that had 
been cultured for 1 week on the chitosan discs were trypsined and placed on the gel at 
a density of 20,000 cell/well. The cells were then incubated for 4 h at 37ºC before 
each well were examined under an optical microscope for total tube length and 
number of branch points per field, both of which was determined by a blinded 
observer using NIH ImageJ 1.46 software. 
 
4.2.9 Statistical analysis 
All experiments were carried out in three replicates (n = 3). The data is presented as 
mean ± standard deviation and analyzed using one-way ANOVA with Tukey’s post 




4.3 Results and discussion 
4.3.1 Amount and retention of growth factor on the functionalized films 
The amount of covalently immobilized BMP-2 and VEGF on the functionalized films 
is presented in Table 4.1. For C1 film, the amount of BMP-2 and VEGF was similar 
at about 66 ng/mg chitosan. C2 film contained approximately four times more BMP-2 
and similar amount of VEGF as the C1 film. C3 film represents the opposite version 
of the C2 film as it contained similar amount of BMP-2 and four times more VEGF 
than the C1 film. The C series films were used to investigate the concentration effects 
of the growth factor on osteoblasts and ECFCs. CCB2 and CCV2 films contained 
approximately double the amount of BMP-2 or VEGF than the C1 film, and these 
films were used to assess the effect of BMP-2 and VEGF separately (i.e. not co-
immobilized on the film), and to identify the nature (synergistic or additive) of the 
BMP-2 and VEGF combination on the C1 film. If the C1 film performs better than 
the CCB2 and CCV2 films, the growth factor combination is considered synergistic. 
Otherwise, if the effects of the C1 film are similar to those of the CCB2 and CCV2 
films, the growth factor co-immobilization is considered to produce an additive effect.  
 
To assess the efficacy of the covalent immobilization, the functionalized films were 
subjected to growth factor release test. After 1 week in PBS, all of the functionalized 
films released less than 15% of the growth factors, with no discernable difference 
among the films (Table 4.1). The similarity in cumulative growth factor release as a 
percentage of initial amount of immobilized growth factor was due to the fact that the 
growth factor release has reached a plateau after 3 weeks, similar to that shown earlier 
in Figure 3.5. On average, more than 83% of the growth factors remained attached to 
the films after 3 weeks in PBS, demonstrating the high retention of the covalently 
immobilized growth factors on the films. As previously shown in Section 3.3.2, 
chitosan degradation in PBS is negligible and thus the growth factor release can be 
attributed to the hydrolysis of amide bonds that link the growth factors and chitosan. 
This high growth factor retention is beneficial for protecting the growth factors from 
degradation and inactivation as well as minimizing the negative impacts of excessive 




4.3.2 Effects of immobilized BMP-2 and VEGF on osteoblasts and ECFCs 
Figure 4.1 shows that the pristine chitosan film can support osteoblast and ECFC 
attachment. In the case of osteoblasts, the finding is in agreement with that reported 
by Fakrhy et al. (2004), providing further evidence that chitosan is a good material for 
osteoblast attachment. On the other hand, the responses of ECFCs to chitosan film 
have not been evaluated prior to the present study. For mature endothelial cells, such 
as human pulmonary and umbilical vein endothelial cells, it has been reported that 
chitosan scaffold did not support the cell attachment, and scaffold pretreatment with 
fibronectin was required to promote cell attachment (Amaral et al., 2009). Since no 
such pretreatment was needed in the present study, it may suggest that ECFCs have 
more favorable attachment behavior on chitosan than mature endothelial cells. Figure 
4.1 also shows that immobilized BMP-2 and VEGF on the C1, C2, and C3 films 
enhanced osteoblast and ECFC attachment as compared to the pristine film. For both 
cell types, the trend of cell attachment was similar, with the C2 and C3 films 
exhibiting a higher level of cell attachment than the C1 film. No significant difference 
in cell attachment was discernible between the C2 and C3 films. The results suggest 
that both immobilized BMP-2 and VEGF promoted osteoblast and ECFC attachment 
in a similar fashion when used at a comparable amount. Figure 4.2 further suggests 
that the combination of BMP-2 and VEGF was additive, as CCB2 and CCV2 
performed similarly to C1 film in stimulating the cell attachment. The BMP-2 
promotion of osteoblast attachment is consistent with that previously reported in 
Chapter 3. On the other hand, the stimulation of ECFC attachment by BMP-2 is 
interesting, as ECFCs are not widely known as BMP-2 targets. However, it has been 
reported that ECFCs express BMP receptors (Smadja et al., 2008). These receptors 
may allow the cells to interact with the immobilized BMP-2, which would explain the 
promotion of the ECFC attachment by BMP-2. In the case of VEGF, it has been 
shown that the cytokine promotes the attachment of mature endothelial cells (Poh et 
al., 2010). The results of the present study suggest that this stimulatory effect may 
also extend to endothelial progenitor cells, including ECFCs. 
 
Effects of the immobilized BMP-2 and VEGF on osteoblast and ECFC proliferation 
are presented in Figure 4.3. Figure 4.3a shows that the number of osteoblast was 
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higher for the C2 and C3 films than for the pristine film after 4 days. At this time 
point, the osteoblast number on the C1 film was similar to that on the pristine film. 
After 8 days, the osteoblasts on the C1, C2, and C3 films were significantly higher 
than on the pristine film. Among the growth factor functionalized films, the highest 
cell number was observed for the C2 and C3 films. Since the number of attached 
osteoblasts was similar at the beginning of the test for all of the films (Section 4.2.4), 
the results indicate that both the immobilized BMP-2 and VEGF had a profound 
stimulatory effect on the osteoblast proliferation. The results were supported by 
Figure 4.4a, which shows that the CCB2 and CCV2 films exhibited a similar level of 
osteoblast proliferation to that of the C1 film.  Figure 4.3b shows that ECFC 
proliferation was similar after 4 days for the CH and C1 films, while that for the C2 
and C3 films were higher than those for the former two films. After 8 days, ECFC 
proliferation was higher for the C1 film than that for the pristine film. As compared to 
the C1 film, ECFC proliferation was higher for the C2 and C3 films. The results 
indicate that the stimulation can be attributed to the immobilized BMP-2 and VEGF. 
Figure 4.4b validates this finding and shows that the stimulatory effect of the growth 
factors on the ECFC proliferation was also additive. In addition to the additive effect, 
the immobilized growth factors are also expected to stimulate the proliferation for a 
longer period than adsorbed growth factors as a result of the higher growth factor 
retention of the former, as demonstrated earlier in Chapter 3. 
 
To assess the effect of the immobilized growth factors on osteoblast differentiation, 
ALP activity and calcium deposition were evaluated and the results are presented in 
Figure 4.5. As shown in Figure 4.5a, ALP activity of osteoblasts on the C1, C2, and 
C3 films was higher than that on the pristine film after 1 week. Among the growth 
factor functionalized films, the highest ALP activity was obtained for osteoblasts that 
were cultured on the C2 film. On the other hand, the ALP activity of osteoblasts on 
the C1 and C3 film was similar. After 2 weeks, the ALP activity of osteoblasts 
increased for all the films tested. The osteoblasts on the functionalized films 
maintained a higher level of ALP activity than those on the pristine film, with the 
highest ALP activity observed for osteoblasts on the C2 film followed by those on the 
C3 and C1 films. The results suggest that both the immobilized BMP-2 and VEGF 
stimulated osteoblast differentiation since ALP is an indicator for the early stage of 





Figure 4.1 Number of attached osteoblasts (a) and ECFCs (b) on the pristine chitosan 
(CH), C1, C2, and C3 films. * and # denote significant difference (P < 0.05) 
compared to the CH and C1 films, respectively. The attached osteoblasts (c-f) and 
ECFCs (g-j) were stained using calcein AM (bar = 100 µm).   
 
 
Figure 4.2 Number of attached osteoblasts (a) and ECFCs (b) on the pristine chitosan 
(CH), C1, CCB2, and CCV2 films. * denotes significant difference (P < 0.05) 





Figure 4.3 Osteoblast (a) and ECFC (b) proliferation on the pristine chitosan (CH), 
C1, C2, and C3 films. * and # denote significant difference (P < 0.05) compared to 
the CH and C1 films, respectively. + indicates significant difference (P < 0.05) 
between the C3 and C2 films. 
 
 
Figure 4.4 Osteoblast (a) and ECFC (b) proliferation on the pristine chitosan (CH), 
C1, CCB2, and CCV2 films after 8 days. * denotes significant difference (P < 0.05) 
compared to the CH film.  + indicates significant difference (P < 0.05) between the 
CCV2 and CCB2 films. 
 
 
Figure 4.5 ALP activity (a) and calcium deposition (b) of osteoblasts on the pristine 
chitosan (CH), C1, C2, and C3 films. * and # denote significant difference (P < 0.05) 
compared to the CH and C1 films, respectively. + indicates significant difference (P < 




Figure 4.6a shows that the osteoblasts on the CCB2 and CCV2 films exhibited a 
higher level of ALP activity than those on the pristine film, confirming that both the 
immobilized BMP-2 and VEGF promoted osteoblast differentiation. Between the two 
immobilized growth factors, a higher level of promotion was exhibited by the 
immobilized BMP-2 since Figure 4.6a shows that the CCB2 film performed better in 
promoting the ALP activity than the CCV2 film. After 3 weeks, the ALP activity of 
the osteoblasts increased for the pristine film, while that for the C1, C2, and C3 films 
decreased as compared to the ALP activity of osteoblasts after 2 weeks (Figure 4.5a). 
The biphasic trend in the ALP activity for the C series films marks the progress of the 
osteoblast differentiation since the ALP activity usually decreases following a 
maximum level at the onset of mineralization by osteoblasts. In the process of 
osteoblast differentiation, ALP is highly expressed in gene as well as protein level in 
the early stage before the osteoblasts are matured (Kular et al., 2012; Capulli et al. 
2014; Sims and Vrahnas, 2014). Consequently, ALP activity is usually assayed in the 
early period of osteoblast culture up to 4 weeks (Bae et al., 2012; Takyar et al., 2013; 
Mathews et al., 2014). In view of this, the 3-week period was chosen since it includes 
the early stage of osteoblast differentiation. In addition to the ALP activity, calcium 
deposition was evaluated to assess the mineralization by osteoblasts. Figure 4.5b 
shows that after 2 weeks, a higher amount of calcium deposits was detected for the 
C1, C2, and C3 films than for the pristine film. The calcium deposition was higher for 
the C2 film than for the C1 film, while that for the C3 film gave similar results as the 
C1 film. The amount of calcium deposits on all of the chitosan films increased after 
three weeks but the trend was similar to that of the second week. Since calcium 
deposition is an indicator of the late stage of osteoblast differentiation (Christenson, 
1997), these results show that the immobilized BMP-2 promotes osteoblast 
differentiation to a greater extent than the immobilized VEGF. Figure 4.6b confirms 
this finding by showing that the CCB2 film, but not the CCV2 film, stimulated higher 
calcium deposition than the pristine film. The results are in line with those reported in 
an in vivo study by Kempen et al. (2009), who found that BMP-2 performed better in 





Figure 4.6 ALP activity after 2 weeks (a) and calcium deposition after 3 weeks (b) of 
osteoblasts on the pristine chitosan (CH), C1, CCB2, and CCV2 films. * and # denote 
significant difference (P < 0.05) compared to the CH and C1 films, respectively. + 
indicates significant difference (P < 0.05) between the CCV2 and CCB2 films. 
 
CD31 and vWF are two of the most common markers for endothelial cells. In this 
study, quantification of CD31 and vWF expression was used to evaluate ECFC 
differentiation into endothelial cells and the results, with supporting immunostaining 
images, are presented in Figure 4.7. As shown in Figure 4.7a and 7b, CD31 and vWF 
expression was stimulated by the immobilized BMP-2 and VEGF in a dose dependent 
fashion. The enhancement in the CD31 and vWF expression is reflected in the 
increase in fluorescence intensity of these markers following immunostaining, as 
shown in Figure 4.7c-j. Figure 4.8 shows that the promotion is a result of an additive 
effect from the co-immobilized BMP-2 and VEGF as the CCB2 and CCV2 films 
performed similarly to the C1 film in stimulating CD31 and vWF expression. 
 
Matrigel assay was carried out to investigate the effects of the immobilized growth 
factor on vessel formation by ECFCs. Figure 4.9 and 4.10 shows that the vessel 
formation, in terms of number of branching points and total tube length, was 
significantly enhanced for the C1, C2, C3, and CCV2 films compared to the pristine 
film, while the CCB2 film and the pristine film gave similar results. These results 
suggest that only the immobilized VEGF had an apparent stimulatory effect on the 
vessel formation by ECFCs. In an earlier work, Smadja et al. (2008) found that 
soluble (non-immobilized) BMP-2 promoted vessel formation by ECFCs. Apart from 
the state of the growth factor (soluble versus immobilized), the difference may arise 
from the duration of BMP-2 treatment. In their work, ECFCs were exposed to BMP-2 




Figure 4.7 (a) CD31 and (b) vWF expression by ECFCs on the pristine chitosan film 
(CH), C1, C2, and C3 films after 1 week. The data in (a) and (b) was normalized with 
that of the CH film. * and # denote significant difference (P < 0.05) compared to the 
CH and C1 films, respectively. Immunofluorescent staining for CD31 (c-f) and vWF 
(g-j) with cell nuclei counterstaining by DAPI (scale bars = 100 µm).  
 
 
Figure 4.8 CD31 and vWF expression by ECFCs on the pristine chitosan film (CH), 
C1, CCB2, and CCV2 films after 1 week. The data was normalized with respect to 






In general, the results show that both immobilized BMP-2 and VEGF had profound 
stimulatory effects on osteoblasts and ECFCs. The immobilized BMP-2 promoted 
osteoblast attachment, proliferation, and differentiation, whereas the immobilized 
VEGF stimulated ECFC attachment, proliferation, differentiation, and tube formation. 
These responses are consistent with the well-documented osteogenic effects of BMP-
2 (Gazzerro and Canalis, 2006) and angiogenic effects of VEGF (Byrne et al., 2005). 
The immobilized BMP-2 also exhibited angiogenic effects, as it promoted ECFC 
attachment, proliferation, and differentiation albeit not tube formation. While Smadja 
et al. (2008) also observed similar effects of soluble BMP-2 on ECFC proliferation 
and differentiation, comparison with VEGF was not available in their study. In our 
study, it was shown immobilized BMP-2 exhibited more limited angiogenic effects 
than those of the immobilized VEGF, since the former did not stimulate tube 
formation by ECFCs. In a reversed role, the immobilized VEGF promoted the 
attachment and proliferation of osteoblasts at a similar level as the immobilized BMP-
2. However, the overall osteogenic effects of the immobilized VEGF were less 
profound than those of the immobilized BMP-2 since the promotion of osteoblast 
differentiation by the former was lower than that of the latter. 
 
No information on the covalent co-immobilization of BMP-2 and VEGF was 
available prior to our study. In an in vivo study involving a dual release of BMP-2 and 
VEGF, Kempen et al. (2009) observed additive effects from a combination of these 
growth factors. This is supported by similar finding in a number of studies that use 
genetically engineered cells expressing BMP-2 and VEGF (Peng et al., 2002; Peng et 
al., 2005; Huang et al., 2005). Our study suggests that the covalent co-immobilization 
did not change the nature of the growth factor interaction since additive effects were 
also observed. Nevertheless, future in vivo studies involving implantation in ectopic 
and orthotopic sites are suggested since a recent study by Patel et al. (2008) has 















Figure 4.9 Matrigel assay showing number of branch points (a) and total tube length 
(b) of ECFCs that were cultured on pristine chitosan (CH), C1, C2, and C3 films after 
1 week. * and # denote significant difference (P < 0.05) compared to the CH and C1 
films, respectively. + indicates significant difference (P < 0.05) between the C3 and 











Figure 4.10 Matrigel assay showing number of branch points (a) and total tube length 
(b) of ECFCs that were cultured on pristine chitosan (CH), C1, CCB2, and CCV2 
films after 1 week. * and # denote significant difference (P < 0.05) compared to the 
CH and C1 films, respectively. + indicates significant difference (P < 0.05) between 
the CCV2 and CCB2 films. 
 
4.4 Summary 
In this study, chitosan films with covalently co-immobilized BMP-2 and VEGF were 
successfully synthesized and their osteogenic as well as angiogenic activity was 
evaluated using osteoblasts and ECFCs. It was found that the immobilized BMP-2 
stimulated osteoblast attachment, proliferation, and differentiation as well as ECFC 
attachment and proliferation. On the other hand, the immobilized VEGF promoted 
ECFC attachment, proliferation, differentiation, and vascularization. It also stimulated 
osteoblast differentiation, albeit to a lesser extent than immobilized BMP-2. When the 
two growth factors were combined, the stimulatory effects were additive. Thus, this 
study demonstrates that covalent co-immobilization of BMP-2 and VEGF on a 
chitosan substrate is a promising approach for simultaneous promotion of 





PROMOTING OSTEOGENIC DIFFERENTIATION OF 
OSTEOBLASTS AND BONE MARROW STEM CELLS 
USING HAP-COATED CMCS SCAFFOLDS 
 
5.1 Introduction 
Development of new bone graft substitutes could solve the limitations of current bone 
graft treatment, as elaborated earlier in Section 2.4. Chitosan with its numerous 
advantageous biological properties (as described in Section 2.2) is a promising 
material as a bone graft substitute. The biological properties of chitosan can be 
improved by combining it with calcium phosphate (CaP) (Chesnutt et al., 2009; 
Zhang and Zhang, 2004; Sendemir-Urkmez and Jamison, 2007; Thein-Han and Misra, 
2009; Zhang and Zhang, 2002), such as HAP (Chesnutt et al., 2009; Thein-Han and 
Misra, 2009). HAP has attracted considerable interest for bone tissue engineering due 
to its compositional similarity with native bone (Ogata et al., 2005). As a 
consequence, many studies have explored the relevance of HAP-based materials for 
bone repair (Ribeiro et al., 2010; Babister et al., 2009; Sethuraman et al., 2007; 
Balasundaram et al., 2006; Hu et al., 2007). Apart from HAP, other forms of CaP, 
such as amorphous calcium phosphate (ACP) (Hu et al., 2007; Ma et al., 2011), 
octacalcium phosphate (OCP) (Liu et al., 2009; Shelton et al., 2006), and β-tricalcium 
phosphate (β –TCP) (Homaeigohar et al., 2008; Kasten et al., 2003) have also been 
investigated for the same purpose. CMCS is known to be more bioactive than 
chitosan (Leonor et al., 2008). This bioactivity allows CMCS to chelate calcium from 
a mineralizing solution containing calcium and phosphate (Muzzarelli et al., 1998; 
Oliveira et al., 2009). As a result, a CMCS-based substrate can readily induce calcium 
phosphate formation from a mineralizing solution. This is highly advantageous when 
compared with less bioactive materials, for which additional treatments or methods 
are required to form substrate-CaP composite. Calcium silicate treatment, for 
example, was required to form CaP on chitosan microparticles (Leonor et al., 2008). 
Alternatively, methods such as co-precipitation of chitosan and CaP were used to 
form chitosan-CaP composite (Chesnutt et al., 2009). To our knowledge, the 
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application of CMCS and calcium phosphate composite in bone tissue engineering is 
relatively unexplored since only a few studies have been conducted on this topic. In 
an earlier work by Muzzarelli et al. (1998), N,N-dicarboxymethyl chitosan  solution 
was mixed with a CaP-containing solution to form a CMCS-CaP complex via 
coprecipitation. This complex was then freeze-dried and tested in vivo as lesion filler 
in sheep’s bone and human teeth. Although the complex promoted osteogenesis in 
both cases, the biocompatibility of the CMCS remains unknown because the 
cytotoxicity of the CMCS (without CaP) was not tested. Furthermore, no conclusion 
on the relationship between the complex properties, such as the CaP morphology, and 
the cell responses can be drawn since only limited characterization was provided. 
More recently, Chen et al. (2002) examined the effect of CMCS membranes on 
normal and keloid skin fibroblasts. Interestingly, they found that the membranes 
promote proliferation of normal skin fibroblasts but inhibits proliferation of keloid 
skin fibroblasts, suggesting that the effects of a CMCS substrate on cells may be cell-
specific. In another study, Oliveira et al. (2009) prepared and characterized HAP-
CMCS composite scaffolds fabricated via an electroless coprecipitation method. 
However, cell responses to these coprecipitated scaffolds have not been documented. 
Thus, further investigations on the cytotoxity/biocompatibility of the CMCS substrate 
and cell responses to CMCS-CaP composites are warranted before applications of 
these promising materials are to be realized. 
 
In terms of structure, the HAP-coated scaffolds prepared in our study are different 
from the coprecipitated scaffolds of the above-mentioned studies (Muzzarelli et al., 
1998; Oliveira et al., 2009). In the coprecipitated scaffolds, a portion of the CaP was 
incorporated inside the scaffold matrix because the scaffolds were formed by mixing 
CMCS and CaP solutions. Hence, not all of the CaP is accessible to the cells. In the 
present study, porous CMCS scaffolds were first prepared before coating with HAP. 
As a result, the HAP coating is formed on the surface of the scaffolds, providing 
better contact between the coating and the cells. This method also allows flexibility in 
changing the morphology and coverage of the HAP coating. The HAP-coated CMCS 
scaffolds can potentially serve as bone grafts due to the combination of porosity and 
the favorable properties of HAP as well as chitosan. The goal of this study was to 
investigate the effects of pristine (non-coated) and HAP-coated CMCS scaffolds on 
osteoblasts and bone marrow stem cells, in particular, the cytotoxicity and 
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osteogenicity of these scaffolds since such information has not been documented. 
Moreover, since the coating properties including morphology and coverage may 
affect the osteogenicity of the scaffolds (Habibovic and de Groot, 2007), this aspect 
was also examined in detail. The investigation was carried out by assessing in vitro 
viability, attachment, proliferation, and differentiation of MC3T3 osteoblasts, and 
osteogenic gene expression analysis of human bone marrow stem cells.  
 
5.2 Experimental section 
5.2.1 Preparation of HAP-coated CMCS scaffolds 
The chemicals were from Merck (Darmstadt, Germany) unless otherwise stated. 
Chitosan with 85% degree of deacetylation (Koyo Chemical, Osaka, Japan) was used 
in the CMCS preparation. CMCS was synthesized according to the method of Chen 
and Park (2003). In brief, 10 g chitosan and 13.5 g NaOH was mixed in 100 ml of 
water/2-propanol mixture (1:4 by volume) and kept at 50°C for 1 h. 
Monochloroacetic acid (in 20 ml 2-propanol) was added dropwise to the mixture over 
30 min. The chitosan and acid were reacted for 4 h at 50°C before 200 ml of 70% 
ethanol was added to stop the reaction. The product was filtered and washed with 70-
90% ethanol and dried under reduced pressure at room temperature. Figure 5.1 shows 
a schematic diagram of the preparation of HAP-coated CMCS scaffold. 2 ml CMCS 
solution (5% w/v in water) in polystyrene dishes with diameter of 5 cm was frozen at 
-20°C for 2 h, immersed overnight in 10 ml CaCl2 5% w/v. This process resulted in 
the ionic crosslinking of the CMCS by the calcium ions. The crosslinked scaffold was 
then carefully washed three times with water. Four different HAP-coated scaffolds 
(CMFb, CMS, CMFa, and CMY) of 3 cm diameter and 300 µm thickness were 
prepared by immersing the CMCS scaffolds in 100 ml of four mineralizing solutions 
listed in Table 5.1 (PFb, S, PFa, and Y) at 37°C in a water bath shaker operating at 
120 rpm for a week. The mineralizing solutions were prepared by dissolving CaCl2 
and KH2PO4 and HEPES according to the compositions given in Table 5.1 with pH 
adjustment using 1 M KOH solution. The compositions of the mineralizing solutions 
were adapted from Lynch et al. (2007) and Yang et al. (2008). PFb and PFa solutions 
were designed as phosphate-rich solutions with similar composition but differing pH. 
HEPES was added to PFb solution as a buffer to maintain its pH. On the other hand, 
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Y and S solutions were designed to contain higher calcium than PFa and PFb 
solutions and to achieve a Ca/P ratio identical to that of HAP, with pH similar to PFa 
and PFb solutions, respectively. In addition to having different pH, Y solution 
contained 28 times more Ca than the S solution. After mineralization, each scaffold 
was gently washed with water and subsequently crosslinked with 5 ml of EDC (4 
mg/ml) and NHS (6 mg/ml) in 0.1 M of 2-(N-morpholino) ethanesulfonic acid (MES) 
for 1 min. The EDC and NHS facilitate crosslinking between the carboxyl groups and 
amino groups of the CMCS to enhance the stability of the scaffolds. After another 
washing cycle with water to remove excess EDC and NHS, the scaffolds were freeze-




Figure 5.1 Preparation of HAP-coated CMCS scaffold. 
 
5.2.2 SEM and energy dispersive X-ray (EDX) analysis 
SEM was employed to evaluate the morphology of the non-coated and HAP-coated 
CMCS scaffolds. This was complemented by phosphorus mapping using EDX to 
view the distribution of the HAP coatings.  Phosphorus was chosen because it was 
only present in the HAP deposits and not in the CMCS scaffold. Thus, it can be used 
in the EDX analysis to differentiate the HAP deposits from the CMCS. On the other 
hand, calcium mapping was not used for this purpose because the CMCS scaffold 
contained calcium before mineralization due to the use of calcium as an ionic 
crosslinker in the CMCS scaffold preparation.  For SEM, the scaffolds were coated 
with platinum before imaging at 15 kV using a JSM 5600LV scanning electron 
microscope (JEOL, Tokyo, Japan) and phosphorus mapping was carried out using an 
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EDX detector (Oxford Instrument, Oxford, UK) attached to the electron microscope. 
SEM images of the coatings at high magnification (50,000×) were obtained using a 
Field Emission SEM (JSM 6700F, JEOL, Japan). 
 
Table 5.1 Ionic composition of mineralizing solutions used in the preparation of 
HAP-coated CMCS scaffolds 
Ion 
Concentration (mM) 
PFb PFa Y S 
K+ 12.7 12.7 25 0.9 
Ca2+ 1 1 42 1.5 
Cl- 2 2 84 3 
HPO42- 12.7 12.7 25 0.9 
HEPES 20 - - 20 
pH 6.58 4.6 4.3 7.0 
Ca/P 0.787 0.787 1.67 1.67 
 
5.2.3 X-ray diffraction (XRD)  
Powder samples of the coated scaffolds were obtained by grinding using a mortar and 
pestle. X-ray diffraction of the powder samples were collected using an XRD-6000 X-
ray diffractometer (Shimadzu, Tokyo, Japan) at a 2θ range of 3-60°, scan rate of 
4°/min, and step size of 0.04° to verify that the coatings were HAP. 
 
5.2.4 Fourier transform infra red (FTIR) spectroscopy  
The scaffolds were ground into powder using a mortar and pestle, mixed with 
potassium bromide in a 1:100 ratio (w/w), and pressed into transparent pellets. 
Transmission spectra of the samples were collected using a Shimadzu FTIR 8400 
spectrophotometer from 4000-400 cm-1 with 32 scans and 4 cm-1 resolution.  
 
5.2.5 Ca/P ratio determination 
The Ca/P ratio was determined using ICP-MS. For this analysis, the coated scaffolds 
were dissolved overnight in 65% nitric acid. The obtained solution was diluted with 
water and filtered through a 0.45 µm filter. Calcium and phosphorus contents of the 
solution were determined using an Agilent Technologies 7500 ICP-MS (Agilent 
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Technologies, CA, USA). The Ca content of the coated CMCS scaffolds arises from 
the Ca deposited as a result of mineralization as well as the CaCl2 used in the 
preparation of the scaffold. Thus, the Ca/P ratio was calculated in two ways, either 
based on the total Ca content, or on the Ca content after subtracting the contribution 
from CaCl2 as determined from the unmineralized scaffold (nCM). These two ways of 
calculation represent two extreme cases, i.e. assuming either all of the Ca in the 
scaffold is due to mineralization and the Ca from the CaCl2 in the scaffold has leached 
out during the mineralization process or all of the Ca from the CaCl2 remains in the 
scaffold. The actual scenario is likely to fall between these two extremes. On the other 
hand, since the scaffolds did not contain P before mineralization, all of the P in the 
scaffold was due to the mineralization. Thus, the P content of the coated CMCS 
scaffolds from the ICP-MS was used directly in the calculation of the Ca/P ratio. The 
results are denoted as uncorrected and corrected ratio, which refers to the value 
without and after subtraction of the Ca content contributed by the scaffold, 
respectively.  
 
5.2.6 Thermogravimetric analysis (TGA) 
TGA was used to determine the amount of HAP based on the inorganic content of the 
coated CMCS scaffolds. The sample was heated in air (100 ml/min) from 25 to 900 
ºC in a DTG-60AH instrument (Shimadzu, Kyoto, Japan) at a heating rate of 50 
ºC/min. The results are presented as the uncorrected and corrected HAP content in a 
similar fashion as Ca/P ratio (Section 5.2.5). 
 
5.2.7 Evaluation of osteoblast functions 
MC3T3-E1 subclone 14 mouse osteoblasts (ATCC, Manassas, VA, USA) were used 
and the osteoblast viability, attachment, proliferation, and differentiation were 
assayed. The coated scaffolds were cut into 10 mm × 10 mm × 300 µm pieces. TCPS 
(Corning, NY, USA) and the non-coated CMCS (nCM) scaffold were used as 
controls. All cell culture reagents were from Invitrogen (Carlsbad, CA, USA) unless 
otherwise stated. Before the osteoblast assays, each scaffold was sterilized using 70% 
ethanol for 1 h, washed three times with sterile PBS, and pre-wetted with a complete 
growth medium (Dulbecco’s modified eagle medium with 10% fetal bovine serum, 
100 mg/ml streptomycin, and 100 U/ml penicillin) for 1 h in a 24-well plate. For the 
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viability assay, each scaffold was then transferred to a new plate, seeded with 10,000 
osteoblasts (in 20 µl of the medium), and maintained in a 5% CO2 incubator at 37 °C 
to allow the osteoblasts to attach to the scaffold for 4 h. This period was selected 
because it was sufficient for osteoblast attachment on the non-coated and coated 
CMCS scaffolds, as will be shown later in Section 5.3.2. During the 4-hour 
attachment period, 20 µl of the medium was applied to each scaffold every 30 min to 
prevent the scaffold from drying. The viability of the osteoblasts was then evaluated 
using Live/Dead Viability Assay Kit (Invitrogen, Carlsbad, CA, USA). In this assay, 
green and red fluorescence represents live and dead cells, respectively. Each scaffold 
was carefully washed with PBS and transferred to a new 24-well plate after the 4-hour 
attachment period. The staining solution (100 µl) was added to the scaffold and 
allowed to incubate for 30 min. The scaffold was then examined under a Leica 
DMLM fluorescence microscope (Leica Microsystems, Wetzlar, Germany).  
 
In the osteoblast attachment assay, different attachment periods of 1, 2, and 4 h were 
used. Except for these attachment periods, the scaffolds sterilization, pretreatment, 
and seeding procedures were identical to those described above. After the attachment 
period, the scaffolds were carefully washed with PBS to remove weakly adherent 
osteoblasts and transferred to a new plate. The number of viable attached osteoblasts 
was then counted using a hemocytometer after the osteoblasts were detached using 
trypsin and stained using trypan blue. To assess osteoblast proliferation, the scaffolds 
were seeded as previously described in the attachment assay and the osteoblasts were 
allowed to attach for 4 h. The seeded scaffolds were then rinsed once with PBS and 
transferred to a new 24-well plate containing 600 µl of the growth medium per well. 
The plate was incubated in the CO2 incubator at 37 °C with medium change every 2-3 
days. At each sampling time (1, 4, 7, and 14 days), the cell number was determined as 
mentioned above. 
 
ALP activity and osteocalcin production by the osteoblasts were used to evaluate the 
osteoblast differentiation. Complete growth medium supplemented with 50 µg/ml 
ascorbic acid and 10 mM β-glycerophosphate was used. With the exception of the 
supplemented medium, the procedures and condition used here were similar to those 
of the proliferation assay. Osteoblasts-seeded CMCS scaffolds were collected 4, 7, 14, 
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and 21 days post-seeding. After the medium was removed, each scaffold was washed 
three times with PBS and homogenized. Cell lysate was extracted by adding a lysis 
buffer (10 mM Tris, 1 mM MgCl2, and 0.02% Triton X in water) to the scaffold 
followed by ultrasonication and centrifugation at 10,000 rpm for 5 min each. The 
ALP activity assay was carried out using the methods described in Section 3.2.8. 
Osteocalcin EIA Kit (Biomedical Technologies, Stoughton, MA, USA) was used as 
per the manufacturer’s instructions to measure total osteocalcin (combined amount 
from the medium and homogenized scaffold), and the result is reported as the 
cumulative amount of osteocalcin produced during a cultivation period. The ALP and 
osteocalcin results were normalized with respect to total protein. The total protein was 
determined using a BCA Protein Assay Kit (Pierce Biotechnology, IL, USA) with 
bovine serum albumin (BSA) as the standard.   
 
5.2.8 Evaluation of gene expression from stem cells  
Poietics® human bone marrow mesenchymal stem cells were purchased from Lonza 
(Walkersville, MD, USA). These multipotent cells have been fully tested for 
adipogenic, chondrogenic, and osteogenic potentiality by the manufacturer. The cells 
were expanded in MSCGM™ Bulletkit® basal (non-osteogenic) stem cell medium 
(Lonza). Each scaffold (10 mm × 10 mm × 300 µm) was seeded with 50,000 stem 
cells from the fourth passage. The number of seeded stem cells was higher than that 
of the osteoblasts described in the previous section in order to improve RNA isolation 
yield for the PCR analysis. Except for the use of the stem cell expansion medium, the 
cell seeding and maintenance procedures were as described in the previous section. 
The nCM scaffold was used as a control, and samples were collected after 1, 4, 7, 14, 
and 21 days. At each time point, the medium was removed and the scaffolds were 
washed three times with PBS and homogenized. Total RNA was then isolated using 
Qiagen RNeasy® Mini Kit (Qiagen, CA, USA) and the amount of isolated RNA was 
measured using Quant-iT™ RNA Assay Kit (Invitrogen, Carlsbad, CA, USA). 
Human-specific primers for β–actin as the housekeeping gene and five osteoblast 
marker genes are listed in Table 5.2. The primers were designed using Primer-BLAST 
(Rozen and Skaletsky, 2000) and purchased from 1st Base Pte Ltd (Singapore). 
Secondary structure formation was minimized and checked using Mfold web server 
(Zuker, 2003). Reverse transcription and quantitative PCR were conducted using 
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iScript™ One-Step RT-PCR Kit with SBYR® Green in an iCycler iQ5 PCR Detection 
System (Bio-Rad Laboratories, CA, USA) as per the manufacturer’s instructions. In 
each PCR reaction mixture, 300 nM each of forward and reverse primer and 10 ng of 
total RNA were used. In each PCR run, amplification efficiency calculation (by serial 
dilution of RNA template) and negative controls (no template and no reverse 
transcriptase controls) were included as quality controls. To facilitate comparisons of 
gene expression across the different time points, all gene expression data was 
normalized against that for nCM scaffold at Day 1 (Pham et al., 2008). The gene 
expression level of each gene at Day 1 for the nCM scaffold was used as the baseline. 
With β-actin as the housekeeping gene, the gene expression was calculated as follows 
(Pfaffl, 2001): 
 
Fold difference = (EP-target)ΔCt-target / (EP-BA)ΔCt-BA  
Here, EP is Pfaffl efficiency (amplification efficiency + 1); target refers to an 
osteoblast marker gene; ΔCt is the difference between the cycle threshold of a gene at 
a time point and that of Day 1; and BA denotes β-actin. 
 
Table 5.2. Primers for PCR analysis of osteogenic marker expression by stem cells 
Genea Accession number Primer sequence (5'-3') 
BA NM_001101.3 Sense AGCCTCGCCTTTGCCGATCC 
  Antisense CATGCCCACCATCACGCCCT 
ALP NM_000478.4 Sense CTCCCACCCACGTCGATTGCAT 
  Antisense TTGCGCTTGGTCTCGCCAGT 
OC NM_199173.3 Sense CGCAGCCACCGAGACACCAT 
  Antisense GACTCTGCACCGCTGGGCTT 
OPN NM_001040058.1 Sense TCTCAGCCAAACGCCGACCA 
  Antisense GGCCACAGCATCTGGGTATTTGTTG 
BMP2 NM_000089.3 Sense TCGCAGGCACTCAGGTCAGC 
  Antisense CTCCGGGTTGTTTTCCCACTCGT 
RUNX2 NM_001200.2 Sense TCACTACCAGCCACCGAGACCA 
  Antisense GGCTGTTTGATGCCATAGTCCCTCC 
aBA ⎯ β-actin, ALP ⎯ alkaline phosphatase, OC ⎯ osteocalcin, OPN ⎯ 
osteopontin, BMP2 ⎯ bone morphogenetic protein 2, RUNX2 ⎯ Runt-related 




5.2.9 Statistical analysis 
Each experiment was carried out with four replicates (n = 4) and the data is presented 
as mean ± standard deviation. All data was analyzed using one-way ANOVA with 
Tukey’s post-hoc test (P < 0.05). 
 
5.3 Results and discussion 
5.3.1 Properties of the coated scaffolds 
The SEM images and phosphorus maps of the scaffolds are provided in Figure 5.2. 
The SEM images show that the scaffolds are porous, as a result of sublimation of ice 
during freeze-drying in the scaffold preparation. The porous structure is important 
when the scaffold is used as a cell attachment platform, since the pores may facilitate 
nutrient and oxygen transport across the scaffold. The presence of HAP deposits is 
evident when the high magnification SEM images of the coated scaffolds (insets of 
Figure 5.2a-c and Figure 5.2g) are compared to that of the non-coated scaffold (inset 
of Figure 5.2i). The induction of HAP deposition is facilitated by the presence of 
carboxyl groups in the CMCS. These carboxyl groups are capable of chelating cations 
such as calcium ions from an ionic solution. This principle was utilized to form the 
scaffold via ionic crosslinking prior to the mineralization. As a result of this ionic 
crosslinking, the scaffold remained stable (did not dissolved) during the 
mineralization. Since ionic crosslinking is based on charge interaction between the 
calcium ions and the carboxylic groups, it does not alter the mineralization capacity of 
the carboxyl groups. On the contrary, it supported the mineralization because the 
calcium ions may contribute to the HAP formation during the mineralization.  
 
The high magnification SEM images also reveal that the morphology of the HAP 
coatings differs significantly. The coatings on the CMFb and CMFa scaffolds 
comprised plate subunits of different sizes and orientations.  The mineralizing 
solutions for these scaffolds are similarly phosphate-rich, and the main difference is 
the pH, which is higher for the mineralizing solution of the CMFb scaffold. While the 
HAP subunits on the CMFb scaffold are arranged horizontally, those on the CMFa 
scaffold are arranged vertically. However, the subunits on the CMFb scaffold are 
significantly smaller than that on the CMFa scaffold. With smaller subunits, the 
surface of the coating on the CMFb scaffold is consequently smoother than those of 
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the CMFa scaffold. On the CMY scaffold, the HAP crystals are present as blocks 
while on the CMS scaffold, the coating is formed from powdery grains of HAP. 
Although the Y and S solutions used for the preparation of the CMY and CMS 
scaffolds, respectively, share the same Ca/P ratio (1.67), the concentrations of Ca and 
P are significantly higher in Y solution (42 mM Ca and 25 mM P) than in S solution 
(1.5 mM Ca and 0.9 mM P) but the pH of the former is lower. This difference in 
concentration and pH may give rise to the differences in morphology between the 
coating on the CMY and CMS scaffolds. The phosphorus maps (Figure 5.2d-f and 
Figure 5.2h) show that the distribution of phosphorus was significantly higher on the 
CMFb and CMS scaffolds than on the CMFa and CMY scaffolds. As the phosphorus 
denotes the presence of the HAP coatings, the phosphorus maps suggest that the HAP 
coverage on the CMFb and CMS scaffolds was significantly higher than on the CMFa 
and CMY scaffolds. 
 
 
Figure 5.2 SEM images (a-c, g, h) and EDX phosphorus maps (d-f, h) of the HAP-
coated CMCS scaffolds. Red dots in the phosphorus maps indicate the presence of 
phosphorus while dark features represent pores of the scaffolds. SEM images of the 
non-coated scaffold (i) are also provided. For the main figures and the insets, the 
magnification is 500× and 50,000×, respectively. Bar = 50 µm for the main figures 




Figure 5.3 presents the XRD spectra of nCM, the four HAP-coated scaffolds, and 
synthetic HAP powder (Sigma-Aldrich, Singapore). The nCM spectrum in Figure 
5.3a exhibits an amorphous peak (*) of CMCS at around 20º (Oliveira et al., 2009). 
As for the coated scaffolds, characteristics peaks of HAP (+) are observed (Leonor et 
al., 2008; Chesnutt et al., 2009). The peaks of CMCS and HAP are consistent with 
those reported earlier in the literature  (Oliveira et al., 2009; Leonor et al., 2008; 
Thein-Han and Misra, 2009). FTIR spectra of HAP, the nCM, and the coated 
scaffolds are shown in Figure 5.4. The phosphate absorption bands PO43- (+) ν3 at 
1027 cm-1 and ν4 at 560 cm-1 are observed for HAP in Figure 5.4a. In the nCM 
spectrum, both characteristic bands of the carboxyl group of the CMCS (*) are 
apparent at 1583 and 1405 cm-1. As expected, all of these peaks of CMCS and HAP 
are observed for the coated scaffolds. The Ca/P ratio and the amount of HAP on the 
coated scaffolds are compiled in Table 5.3. Since the CMCS scaffolds contained 
calcium prior to the mineralization, there is a possibility that some or all of the 
calcium from the scaffold would have leached out during the mineralization. 
However, since the mineralizing solutions contain calcium, it is difficult to 
differentiate the calcium originally in the scaffold from that of the mineralizing 
solutions. In addition, the rate of calcium leaching may be different in the different 
mineralizing solutions since they have different pH and ionic concentration. To 
provide a rough estimate of the Ca/P ratio of the mineral deposits and amount of HAP 
formed on the coated CMCS scaffolds, the minimum and maximum values are 
provided in Table 5.3 based on the corrected and uncorrected amount of calcium in 
the scaffold, respectively. As shown in the Table, both corrected and uncorrected 
Ca/P ratios of the CaP deposits on the scaffolds are close to the theoretical value of 
1.67 for HAP. Thus, the XRD and FTIR spectra as well as the Ca/P ratio verify that 
the scaffolds were coated with HAP. The corrected and uncorrected amount of HAP 
was the highest for the CMFb and CMS scaffolds, followed by the CMFa scaffold, 
and the least for the CMY scaffold. This trend in the variation of HAP deposited on 
the various scaffold correlates well with the HAP coverage shown by the phosphorus 










Figure 5.3 XRD spectra of the non-coated scaffold (a), the HAP-coated scaffolds (b-




Figure 5.4 FTIR spectra of HAP (a), the non-coated scaffold (b), and the HAP-coated 





Table 5.3 Ca/P ratio and amount of HAP on the coated CMCS scaffolds. 
Scaffold 
Ca/P (n = 4)  Amount (%, n = 4)a 
Corrected b Uncorrectedc  Correctedb Uncorrectedc 
CMFb  1.62 ± 0.15  1.76 ± 0.15     26.43 ± 8.67 41.11 ± 8.67 
CMS  1.73 ± 0.15  1.86 ± 0.15     30.54 ± 3.05 45.22 ± 3.05 
CMFa  1.60 ± 0.11  1.67 ± 0.11     11.98 ± 1.16 26.66 ± 1.16 
CMY  1.61 ± 0.12  1.68 ± 0.12       5.72 ± 0.25 20.40 ± 0.25 
a based on total weight of the scaffold; b with subtraction and c without subtraction of 
Ca content in the scaffold prior to the mineralization.  
 
5.3.2 Effects of the coated scaffolds on osteoblasts 
Figure 5.5 shows the results of the Live/Dead staining of the osteoblasts after 4 h 
attachment on the TCPS, nCM, and HAP-coated scaffolds. The results indicate that 
the non-coated CMCS scaffold is not cytotoxic to osteoblasts since the majority of the 
osteoblasts on the nCM scaffolds were viable (Figure 5.5b) and no significant number 
of dead cells was detected (Figure 5.5e). A similar conclusion can be inferred from 
Figure 5.5 for the HAP-coated scaffolds.  Since HAP has similar composition with 
native bone (Ogata et al., 2005) this result is expected and is in agreement with 
previous studies (Ribeiro et al., 2010). No apparent difference in the morphology of 
the osteoblasts on the CMCS scaffolds (Figure 5.5b-c, 5.5g-i) and those on the TCPS 
(Figure 5.5a) was observed. 
 
The results of osteoblast attachment assay are depicted in Figure 5.6a. After one hour, 
about 50% of the osteoblasts (on average, from the initial 10,000 cells seeded on each 
scaffold) were attached on all surfaces with no significant difference in cell number 
observed across the experimental groups. More osteoblasts attached on the surfaces 
after a 2-hour period than after one hour. After the 2-hour period, the cell number for 
the nCM scaffold was significantly lower than that for the TCPS.  Among the coated 
scaffolds, the cell number was highest for the CMFb scaffold, followed by that for the 
CMS scaffold, and the least for the CMFa and CMY scaffolds. As compared to the 
cell numbers for the TCPS and the nCM scaffold, the number for the CMFb scaffold 
was similar to the former and significantly higher than the latter. On the other hand, 
the cell numbers for the CMFa and CMY scaffolds were significantly lower than that 
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for the TCPS and similar to that for the nCM scaffold.  When the attachment period 
was extended to 4 h, the CMFb and CMS scaffolds supported similar numbers of 
osteoblasts as the TCPS, but the numbers for the CMFa and CMY scaffolds are still 
lower. Nevertheless, more than 76% of the seeded osteoblasts had attached on all 
surfaces. Based on these results, 4 h were considered sufficient for osteoblast 
attachment on the CMCS scaffolds.  
 
 
Figure 5.5 Fluorescence microscopy images of osteoblasts stained using the 
Live/Dead kit after 4-hour attachment on TCPS, the non-coated CMCS (nCM) 
scaffold, and the HAP-coated scaffolds under the green filter for viable cells (a-c, g-i) 
and red filter for dead cells (d-f, j-l). Bar = 100 µm.  
 
The 4-hour osteoblast attachment results also suggest that the non-coated CMCS 
scaffold is a suitable substrate for osteoblast attachment since the number of attached 
osteoblasts was comparable to that on TCPS. The suitability of the CMCS scaffold for 
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supporting osteoblast attachment is not surprising since chitosan, the base material of 
CMCS, supports osteoblast attachment (Fakhry et al., 2004). Moreover, the presence 
of calcium in the CMCS scaffold may have further improved this effect since 
calcium-containing surface was reported to enhance osteoblast attachment (Feng et 
al., 2004). Among the coated scaffolds, the CMFb scaffold was the best scaffold for 
osteoblast attachment. As early as 2 h after seeding, the CMFb scaffold outperformed 
the other coated scaffolds and the nCM scaffold in osteoblast attachment.  A high 
coverage of HAP seems to be beneficial for osteoblast attachment since a higher 
degree of osteoblast attachment was observed for the CMFb and CMS scaffolds, 
which have higher HAP coverage than the CMFa and CMY scaffolds.  
 
 
Figure 5.6 Comparison of (a) osteoblast attachment, (b) osteoblast proliferation, (c) 
ALP activity, and (d) cumulative osteocalcin production obtained with the HAP-
coated scaffolds. * and # denote significant difference (P < 0.05, n = 4) compared to 
TCPS and nCM scaffold, respectively. 
 
Osteoblast proliferation profiles on the coated CMCS scaffolds are provided in Figure 
5.6b. During the first day of cultivation, the extent of proliferation was low since the 
numbers of cells for all experimental groups were only slightly increased from the 
number of initially seeded cells. No significant difference was observed across the 
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groups in this period. From Day 2 to 4, osteoblasts proliferated significantly faster on 
the CMFb and CMS scaffolds than on TCPS, nCM, and the other two coated 
scaffolds. The numbers for the nCM, CMFa, and CMY scaffolds were not 
significantly different from that for the TCPS after 4 days. From Day 5 to 7, 
considerable proliferation was observed only for the TCPS as well as the CMFa and 
CMY scaffolds. For the nCM, CMFb, and CMS scaffolds, the numbers after 7 days 
did not differ significantly from those after 4 days. The osteoblast number for the 
nCM scaffold after 7 days was significantly lower than those for the other surfaces. 
Extending the cultivation period to 14 days resulted in significant increase in cell 
number only for the nCM scaffold. At this time point, the cell numbers in all groups 
were similar. The proliferation profiles revealed that the CMFb and CMS scaffolds 
accelerated osteoblast proliferation better than the CMFa and CMY scaffolds, 
suggesting that a high coverage of HAP may be useful in promoting osteoblast 
proliferation in addition to attachment.  
 
The ALP activity of osteoblasts on the TCPS, non-coated, and the coated scaffolds is 
compared in Figure 5.6c. After 4 days, the ALP activity of osteoblasts on the CMFb 
scaffold was significantly higher than that of the other experimental groups. After 7 
days, the ALP activity in all groups was significantly higher than that after 4 days, 
and the ALP activity on all coated scaffolds was significantly higher than that on 
TCPS and nCM scaffold. No significant difference in the ALP activity was observed 
among the coated scaffolds. The ALP activity in all groups was similar after 14 days. 
Since ALP activity is indicative of osteoblast activity and the early stage of osteoblast 
differentiation (Christenson, 1997), these results suggest that the HAP-coated 
scaffolds can promote osteoblast differentiation earlier than TCPS and non-coated 
CMCS scaffold. Similar outcomes regarding induction of higher ALP activity in cells 
grown on HAP substrate were also reported elsewhere (Brugge et al., 2003), and the 
release of calcium and phosphate ions from partial dissolution of the HAP was 
proposed as the possible cause for the enhancement in ALP activity. Among the 
coated scaffolds, only limited differences were observed, based on the 7-day and 14-
day results in Figure 5.6c. The CMFb scaffold was the most effective in promoting 
ALP activity, by promoting the differentiation earlier than the other coated scaffolds 




Mature osteoblasts produce mineralized bone matrix, and components of this matrix, 
such as calcium and osteocalcin, are usually used as markers for the late stage of 
osteoblast differentiation (Christenson, 1997). In this study, osteocalcin was preferred 
over calcium as a marker since the CMCS scaffolds contain calcium, which renders 
the calcium assay unreliable in assessing osteoblast differentiation (Beucken et al., 
2007). During the differentiation, most of the osteocalcin is deposited on the matrix 
while a fraction of it is released into circulation (Zhang and Zhang, 2004). Therefore, 
in this study, the osteocalcin deposited on the scaffolds and released into the medium 
were measured and a combined amount was reported as the cumulative osteocalcin, as 
presented in Figure 5.6d. After 7 days, low osteocalcin production (less than 0.2 
ng/mg protein) was observed across all experimental groups, except for the CMFb 
scaffold which exhibited a significantly higher production of osteocalcin. After 14 
days, the osteocalcin production increased for all groups. Comparable osteocalcin 
production was obtained for the TCPS and the nCM scaffold, indicating that the non-
coated CMCS scaffold supports the late stage of osteoblast differentiation in a similar 
manner as the TCPS. In contrast, significantly higher osteocalcin production was 
observed for the HAP-coated scaffolds. In particular, the osteocalcin production for 
the CMFb scaffold was significantly higher than that for the other coated scaffolds, 
suggesting that the CMFb scaffold was the best performer in promoting the late 
osteoblast differentiation. When the culture was extended to 21 days, the osteocalcin 
production continued to rise for all groups, but the osteocalcin production for the 
HAP-coated scaffolds remained significantly higher than that for the TCPS and nCM 
scaffold. This clearly indicates that the HAP coating enhances the late stage of 
osteoblast differentiation. By comparing Figure 5.6c and 5.6d, it is evident that the 
HAP coating had a more profound effect on the late stage than the early stage of 
osteoblast differentiation. While the ALP activity for the HAP-coated scaffolds was 
similar to that on the nCM scaffold after 14 days (Figure 5.6c), the osteocalcin 
production for all of the coated scaffolds was significantly higher after 14 and 21 days 
(Figure 5.6d). Similar findings were also reported for osteoblasts seeded on chitosan-
nanohydroxyapatite scaffolds (Chesnutt et al., 2009). Moreover, the comparisons 
between Figure 5.6c and 5.6d generally suggest that the HAP coatings stimulate 
osteoblast differentiation in a similar fashion regardless of the variations in 
morphology and coverage. This can be deduced from the limited differences among 
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the HAP coatings (with the exception of the CMFb scaffold) in inducing both early 
(ALP activity results) and late (osteocalcin results) stages of osteoblast differentiation.  
 
When the results of attachment, proliferation, and differentiation of osteoblasts are 
considered altogether, it can be concluded that the HAP-coated CMCS scaffolds 
promote osteoblast activities more than the non-coated CMCS scaffold, and the 
CMFb scaffold was the best performer among the HAP-coated scaffolds. The main 
improvement in osteoblast activity by the coated scaffolds was in the late stage of 
osteoblast differentiation since the osteocalcin production by osteoblasts on all of the 
coated scaffolds was clearly higher than that on the non-coated scaffold. The results 
also show that the capability of the scaffolds to support osteoblast attachment and 
proliferation was affected by the coating coverage. This is in contrast with the 
osteoblast differentiation and may suggest that osteoblast differentiation is less 
sensitive to the variation in the HAP properties than osteoblast attachment and 
proliferation. Based on these results, the HAP coated scaffolds are best suited to 
promote osteoblast differentiation since they provide greater enhancement of this 
process compared to osteoblast attachment and proliferation. 
 
5.3.3 Effects of the coated scaffolds on bone marrow stem cells 
Gene expression profiles of five osteoblast markers from bone marrow stem cells 
cultivated on the CMCS scaffolds are shown in Figure 5.7. The profiles for the nCM 
scaffold indicate that the non-coated CMCS scaffold promotes osteoblastic 
differentiation of the stem cells since significantly higher gene expression than the 
baseline (denoted by # in Figure 5.7) are observed for all five osteoblast marker genes 
within a 21-day period. As stated in Section 5.2.8, for each gene, the baseline is taken 
as the expression level for the nCM scaffold at Day 1. Moreover, the results in Figure 
5.7 suggest that the HAP coatings enhance the osteoblastic differentiation of the stem 
cells more than the nCM scaffold. Figure 5.7c-e show that the stem cells on the coated 
scaffolds in general expressed substantially higher levels of OPN, OC, and BMP2 
genes than those on the nCM scaffold over the 21 day period. Additionally, 
significantly higher gene expression of these genes than the baseline was observed as 
early as Day 1 for the coated scaffolds. On the contrary, this enhancement effect was 
only exhibited by the stem cells on the nCM scaffold after a minimum of 7 days. The 
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effects on the RUNX2 and ALP genes were less profound, as shown in Figure 5.7a 
and 5.7b. OC and OPN expression marks the late stage of osteoblast differentiation 
and BMP2 is an important factor for osteoblast maturation (Deschaseaux et al., 2009). 
On the other hand, ALP and RUNX2 are expressed at the early stage of osteoblast 
differentiation. Therefore, the gene expression profiles suggest that the enhancement 
and acceleration of the osteoblastic differentiation of the stem cells by the coatings 
occurred predominantly at the late rather than the early stage of the osteoblast 
differentiation pathway. A similar pattern of gene expression was also observed for 
bone marrow stem cells cultured in an osteogenic medium containing ascorbic acid, 
dexamethasone, and β–glycerophosphate (Siggers et al., 2010). Since the medium 
used in the present study was a basal medium without osteogenic supplements, this 
similarity suggests that the HAP coatings may have induced osteoblastic 
differentiation of the stem cells via a similar mechanism as a standard osteogenic 
medium. Among the different types of coatings, only limited differences in the gene 
expression were observed (Figure 5.7), indicating that osteoblastic differentiation of 
the stem cells is not sensitive to the variations in the properties of the coatings. In line 
with the previously discussed outcomes of the osteoblast differentiation assays in 
Section 5.3.2, the gene expression results suggest that the HAP-coated CMCS 
scaffolds promote osteoblastic differentiation of both osteoblasts and bone marrow 




CMCS was used to fabricate porous scaffolds, and the presence of carboxyl groups in 
CMCS facilitates the deposition of an HAP coating from a mineralizing solution. 
HAP coatings of different morphology and coverage were obtained using different 
mineralizing solutions. Both the non-coated and HAP-coated CMCS scaffolds are 
biocompatible. The CMCS scaffold supports osteoblast attachment, proliferation, and 
differentiation as well as osteoblastic differentiation of bone marrow stem cells, but 
substantial improvements can be achieved with a coating of HAP. The main 
improvement was the significant enhancement of osteoblast and bone marrow stem 






Figure 5.7 Gene expression of osteoblast markers by stem cells seeded on the HAP-
coated scaffolds as determined by PCR (n = 4). All data are presented as fold 
difference in gene expression after normalization to the Day 1 results of the nCM 
scaffold. * and # indicate significant difference (P < 0.05) compared to the nCM 





BIOACTIVITY STUDY OF MTA-COATED CMCS 
SCAFFOLDS AS DENTIN REMINERALIZATION 
PATCH IN A TOOTH MODEL 
 
6.1 Introduction 
Dentin is a mineralized connective tissue consisting of microscopic channels, known 
as dentinal tubules. It forms the major bulk of tooth structure, with collagen and HAP 
as the main constituents (Dorozhkin and Epple, 2002). Dentinal tubules contain 
dentinal fluid, which has a composition similar to blood plasma (Marshall et al., 
1997). The fluid allows dentin to be permeable and maintains dentin hydration (Linde 
and Goldberg, 1993). With the advances in tissue engineering and regenerative 
medicine, some efforts have been directed to the regeneration of the tooth structure, 
including the use of scaffold for dentin regeneration (Moioli et al., 2007). An 
optimum scaffold for dentin regeneration needs to be bioactive, in addition to other 
requirements, such as being non-toxic, biodegradable, and biocompatible (Moioli et 
al., 2007; Mason and Edwards, 2009). Bioactivity enables the scaffold to integrate 
into the surrounding host dentin tissue (Lluch et al., 2009) and is marked by 
biomineralization of HAP on the scaffold surface when it is in contact with body 
fluids (Kokubo and Takadama, 2006).  
 
Some materials including alginate, hyaluronic acid, collagen, and synthetic polymers, 
such as polyglycolic acid and composite of ethyl methacrylate polymers with silanol 
containing ceramics, have been investigated for dentin regeneration (Moioli et al., 
2007; Lluch et al., 2009). Although the bioactivity of some of these materials has 
been tested in vitro in bulk solution, to our knowledge, none has its bioactivity tested 
in a tooth model, which may be a better representation of the clinical environment. 
Therefore, the bioactivity CMCS scaffold for potential use as dentin regeneration 
patch was assessed in a tooth model in this study and the results were compared to 
those in bulk solution. CMCS is preferred over chitosan for this study due to its 
ability to induce HAP formation, as demonstrated in Chapter 5. Furthermore, the 
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prospect of improving the bioactivity of CMCS by incorporating mineral trioxide 
aggregate (MTA), a dental material with an excellent mineralization potential (Tay et 
al., 2007; Roberts et al., 2008), was also explored. To facilitate fluid transfer across 
the scaffolds during dental application, the scaffolds used in this study (with average 
thickness of 100 µm) were three times thinner than those used for supporting 
osteoblasts and stem cells growth as described in Chapter 5. While mineralized 
scaffolds were used in Chapter 5, the scaffolds in this study were in the non-
mineralized form since they were designed to utilize the dentinal fluid for 
mineralization during in vivo application. 
 
6.2 Experimental section 
6.2.1 Preparation of CMCS scaffolds 
CMCS was synthesized using the procedures described in Section 5.2.1. Two types of 
CMCS scaffold, namely calcium-crosslinked CMCS (CaC) and MTA-coated CaC 
(CaMT) scaffolds, were prepared. To prepare CaC hydrogel, 1 ml of CMCS solution 
(5% w/v in water) in polystyrene dishes (Corning Inc., Corning, USA) was frozen at -
20°C for 2 h, followed by overnight immersion in 5% w/v CaCl2 (Merck). CaMT 
hydrogel was prepared similarly with the exception that 1 mg/ml MTA (ProRoot® 
MTA, Densply, Tulsa, OK, USA) in CaCl2 was used in place of CaCl2. The hydrogels 
were gently washed with water before they were freeze-dried to form the scaffolds. 
The scaffolds had two sides: (1) the air side and (2) the mold side. The MTA to 
CMCS weight ratio in a CaMT scaffold was 1:100 (1% w/w coating of MTA).  
 
6.2.2 Scaffold mineralization in the tooth model and bulk solution 
Extracted intact non-carious mandibular first molar teeth with divergent roots were 
used for the construction of tooth models in this study. The extraction and use of the 
teeth has been approved by The Institutional Review Board of the National University 
of Singapore. Figure 6.1 shows the schematic diagram of the tooth model. 
Mineralization experiments were carried out for 5 different mineralization periods (1, 
3, 5, 7, and 14 days) and 8 teeth were used for each mineralization period.  On each 
tooth, two occlusal cavities (3 mm × 2 mm × 3 mm) were prepared for the placement 
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of CaC and CaMT scaffolds, respectively. The average remaining dentin thickness 
(RDT) was 1.79 mm (range 1.63-1.92 mm). The RDT was determined after the 
experiments by sectioning the teeth and measuring the average distance from the 
cavity floor to the pulp chamber using a calliper. The placement of CaC and CaMT 
scaffolds on the same tooth will allow better comparison of mineralization results by 
minimizing effects arising from possible structural differences among the teeth. 
Straight fissure tungsten carbide burs were used in a contra-angle handpiece under 
water-cooling to prepare the cavities. To facilitate fluid transport, approximately 2 
mm of the apical section of the roots was removed using a thin diamond disc in a 
slow-speed contra-angle handpiece and the tissue remnants from the root canal and 
the pulp chamber was removed using barbed broaches and saline irrigation. One piece 
each of CaC and CaMT scaffolds (3 mm × 2 mm × ~100 µm) were placed into the 
cavities with the air side of the scaffold on the bottom of the cavities. In total, 16 
scaffolds (8 each of CaC and CaMT scaffolds, n = 8) were tested for each 
mineralization period. After the placement of the scaffolds, the cavities were capped 
with silicon rubber adhesive (3M, St. Paul, MN, USA) reinforced by a layer of 
parafilm to ensure leak-proof sealing of the occlusal side of the cavities. 
 
 
Figure 6.1 Diagram of the tooth model showing the placement of the scaffold in 
dentin cavity and the flow direction of mineralizing solution. 
 
Simulated body fluid (SBF) with ionic composition representing human blood plasma 
(Table 6.1) was prepared as described by Kokuko and Takadama (2006). This 
solution was selected since dentinal fluid shares similar composition with the blood 
plasma (Marshall et al., 1997). SBF was maintained at 37°C and circulated at 1 
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ml/min through the pulp chamber from a fluid reservoir containing 1 liter of the 
solution, using plastic tubing connected to a peristaltic pump. To reach the scaffolds, 
SBF diffused coronally from the pulp chamber through the dentinal tubules. A pilot 
experiment was conducted to test the permeability of dentin under the cavity before 
the actual experiments were started. In the pilot experiment, the effectiveness of the 
diffusion was checked using cotton pellets in place of the scaffolds with the wetting 
of the pellets indicating successful diffusion. SBF in the reservoir was replenished 
every 3 days during the mineralization experiments. For bulk mineralization, a piece 
of CaC or CaMT scaffold (1 cm × 1 cm × ~100 µm) was submerged in 20 ml of SBF 
in a 50 ml polystyrene tube. The tubes were placed in a water bath incubator shaker at 
120 rpm with the temperature set at 37°C for 7 days. After mineralization, the 
scaffolds were retrieved, washed with water, and dried in a hot air oven at 60°C until 
constant weight was obtained, and then subjected to further investigation (Section 
6.2.3). 
 
Table 6.1 Ionic composition of SBF 












6.2.3 Scaffold characterization  
The degree of substitution in CMCS was calculated based on the elemental analysis of 
CMCS and chitosan using a Perkin Elmer 2400 Series II CHNS/O Elemental 
Analyzer (Perkin Elmer, Waltham, MA, USA). In this study, the degree of 
substitution represents the number of carboxyl groups per CMCS unit. Agilent 
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Technologies 7500 (Agilent Technologies, Santa Clara, CA, USA) ICP-MS was used 
to quantify the amount of Ca in CaC and CaMT scaffolds prior to the mineralization. 
It was also used to quantify P content of the scaffolds following the mineralization. 
Since both the CaC and CaMT scaffolds contain no P prior to the mineralization, the 
P content of the CMCS scaffolds arises from the CaP deposited on the scaffolds 
during the mineralization and can be related to the amount of the deposited CaP. The 
scaffolds were dissolved overnight using 65% nitric acid. The resultant solution was 
diluted and filtered with 0.45 µm filter before analysis. The quantification results are 
reported in mg of Ca or P per gram dry weight of the scaffold. Morphology of the 
scaffold was analyzed using SEM (JEOL 5600LV, JEOL, Tokyo, Japan). The 
scaffold was sputter-coated with platinum before imaging was carried out using the 
electron microscope and elemental analysis using an EDX detector (Oxford 
Instrument, Oxford, UK) attached to the microscope, at 15 kV. The EDX data were 
processed into elemental composition (in atomic percentage) using Inca EDX 
software (Oxford Instrument, Oxford, UK). Ca/P ratios of the mineral deposits were 
calculated based on the elemental composition data from EDX and reported as an 
average from 8 pieces of scaffold per mineralization period.  For cross sectional 
analysis, the scaffolds were fractured in liquid nitrogen before SEM imaging. 
Mercury porosimetry was used to characterize the porosity of the scaffolds. In 
addition to the porosity, the porosimetry experiments also provided information on 
the surface area and density of the scaffolds. Pieces of a scaffold (5 cm × 5 cm × ~100 
µm) were loaded into a 3 ml penetrometer and the porosity was measured using 
Micromeritics AutoPore III 9420 Mercury Porosimeter (Micromeritics, Norcross, GA, 
USA) with measurement pressure ranging from 0.4 to 60,000 psia. 
 
6.2.4 Statistical analysis 
For each type of scaffold, quantitative data were reported as mean ± standard 
deviation (n = 8). The data were analyzed using the two-sample t-test and were 
considered significant if P < 0.05. G*Power 3 power analysis program (Faul et al., 
2007) was used to ensure that the obtained P values were reliable, with power > 0.8 as 
the passing criterion. 
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6.3 Results and discussion 
6.3.1 Properties of the CMCS scaffolds 
During the carboxymethylation, the carboxyl groups are grafted to chitosan at 6-O-, 
2-O-, and 2-N- positions. According to an earlier study by Chen and Park (2003), 
more than half of the carboxyl groups are located at the 6-O- position when the 
carboxymethylation is carried out at the conditions used in this study (50°C of 
reaction temperature and 1:4 2-propanol/water mixture).  The elemental analysis 
reveals that the degree of carboxyl substitution of the CMCS in this study was 1.08, 
suggesting that more than one carboxyl groups are present per CMCS unit. The high 
degree of carboxylic substitution of the CMCS was beneficial for chelating calcium 
(Wan et al., 1996, Chen and Park, 2003), which was essential for mineralization of the 
scaffold. The average Ca content in CaC and CaMT scaffolds was 147.7 ± 2.0 mg 
Ca/g and 152.2 ± 2.5 mg Ca/g of scaffold, respectively. Numerous pores were 
observed in the scaffolds (Figure 6.2). More pore openings were observed on the air 
side than the mold side of the scaffolds (which is evident by comparing Figure 6.2a 
with 6.2b and Figure 6.2d with 6.2e). Figure 6.2c and 6.2f show that the pores were 
interconnected with no apparent difference in porosity across the thickness of the 
scaffolds. In Figure 6.2c, a 300 µm scaffold was used for illustration. Deposits of 
MTA (as small irregular particles with size ranging from few hundreds nanometers to 
10 microns) were observed on the air side of CaMT scaffold (Figure 6.2d) and in the 
pores as well (Figure 6.2f).  
 
Mercury porosimetry results confirm that the CaC scaffold was porous with porosity 
of 37% (Table 6.2). Only large pores with size ranging from 30 to 88 microns were 
observed. This corresponds to a fairly narrow pore size distribution in terms of both 
volume and area. Both the pore size distribution and the average pore diameter from 
the porosimetry measurements are in agreement with the apparent pore sizes in the 
SEM images in Figure 6.2. The specific surface area of the scaffold was significantly 
increased with the presence of the pores. As compared to the apparent surface area, 
there was an 88% increase in the specific surface area from 0.157 to 0.295 m2/g. The 
porosity of CaMT scaffold was not significantly different (P > 0.05) from that of CaC 
scaffold, indicating that the 1% w/w MTA coating did not alter the pore structure of 
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CaMT scaffold. This is supported by the SEM images in Figure 6.2, which shows that 
the porosity of CaC and CaMT scaffolds were similar. 
 
 
Figure 6.2 SEM images of (a,d) air side, (b,e) mold side, and (c,f) cross section of 




Table 6.2 Mercury porosimetry results of CaC scaffold 
Average pore diameter 56.6 µm 
Total pore area 0.138 m2/g 
Apparent surface area* 0.157 m2/g 
Specific surface area+  0.295 m2/g 
Total pore volume 1.95 ml/g 
Skeletal density* 0.184 g/ml 
Bulk density+ 0.115 g/ml 
Porosity 37% 
*Excluding pore contribution. +Including pore contribution. 
 
6.3.2 Scaffold mineralization in the tooth model and bulk solution 
The deposition of mineral on CaC scaffold in the tooth model can be observed from 
the SEM images (Figure 6.3a-f) since there was no mineral deposit on CaC scaffold 
prior to the mineralization (Figure 6.3a). As for CaMT scaffold, the presence of CaP 
would not be as obvious from the SEM images (Figure 6.3g-l) since MTA was coated 
on the scaffold before mineralization (Figure 6.3g). Since EDX analysis of MTA 
confirmed that it contains no P, the presence of P was used as an indicator of CaP 
formation on CaMT scaffold. CaP formation was apparent after 3 days of 
mineralization for both CaC and CaMT scaffolds although the coverage of the 
mineral was still low (Figure 6.3c and 6.3i). The presence of CaP crystals at this 
period on the scaffolds was confirmed by Ca and P peaks in the EDX scan, as 
illustrated in Figure 6.4a-c for CaMT scaffold. Figure 6.4a also shows the peaks of 
Na, S, and Cl from SBF (Table 6.1) as well as Si and Al from MTA (Camilleri et al., 
2005; Tay et al., 2007). MTA was still detectable on CaMT scaffold due to the 
minimal deposition of CaP at this stage. When the coating of CaP crystals thickened 
at the later stage of mineralization, the signature peaks of MTA were no longer 
discernible (Figure 6.4b and 6.4c). Similar observation was reported by Leonor et al. 
(2008) in their mineralization studies on chitosan microparticles. High Ca/P ratio 
(2.18 for CaC scaffold and 2.12 for CaMT scaffold), as shown in Table 6.3, was 
observed for crystals formed on both scaffolds after 3 days of mineralization. The 
Ca/P ratio suggests that the crystals were probably ACP (Dorozkin and Epple, 2002). 
After 5 days, more deposits were observed (Figure 6.3d and 6.3j, with the Ca/P ratios 
of 1.38 for CaC scaffold and 1.44 for CaMT scaffold (Table 6.3). The ratios are close 
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to the theoretical value of 1.33 for OCP. HAP formation was detected after 7 days of 
mineralization (Figure 6.3e and 6.3k), as indicated by a Ca/P ratios of 1.60 for CaC 
scaffold and 1.65 for CaMT scaffold (Figure 6.4c). These ratios agree well with the 
value of 1.67 measured for pure HAP (Figure 6.4d). The Ca/P ratio of the deposits on 
the scaffolds after 7 and 14 days were similar. The Ca/P results suggest that HAP 
formation on the scaffold was via transformation from OCP, supporting the 
proposition that HAP formation is an indirect process, in which intermediate phases, 
such as ACP, brushite, and OCP, are first formed before CaP crystals mature by 
hydrolysis to form HAP (Lynch et al., 2007; Camilleri et al., 2005). As illustrated in 
Figure 6.3c, impurities such as Na and Cl can be found in HAP formed on the CMCS 
scaffolds. These impurities are the products of ionic substitutions of Ca, phosphate, 
and hydroxide of the HAP by ions from the SBF solution (Dorozhkin and Epple, 
2002; Tay et al., 2007).  
 
 
Figure 6.3 SEM images of the CaC (a-f) and CaMT (g-l) before and after 




Figure 6.4 EDX spectra of CaP deposits on CaMT scaffold after mineralization for 
(a) 3 days, (b) 5 days, and (c) 7 days in the tooth model. EDX spectrum of pure HAP 
(d) is provided for comparison. 
 
Table 6.3 Ca/P ratio of CaP crystals formed on CaC and CaMT scaffolds that were 
mineralized in the tooth model over 14 days. 
Mineralization Ca/P ratio (n = 8) 
period (days) CaC CaMT 
1 P not detected P not detected 
3 2.18 ± 0.11 2.12 ± 0.15 
5 1.38 ± 0.10 1.44 ± 0.12 
7 1.60 ± 0.08 1.65 ± 0.11 
14 1.63 ± 0.05 1.66 ± 0.15 
 
SEM images of the CMCS scaffolds after 7 days mineralization in the tooth model 
and bulk solution are shown in Figure 6.5. Comparing Figure 6.5c with 6.5a and 
Figure 6.5d with 6.5b, the CaP deposits on CaMT were denser than those found on 
CaC scaffold for the tooth model as well as the bulk solution. The CaP minerals 
formed on CaC and CaMT scaffolds in the tooth model (Figure 6.5a and 6.5c) appear 
to have a more compact structure than those formed in bulk SBF solution (Figure 6.5b 
and 6.5d). The Ca/P ratios of the CaP deposits on the CaC and CaMT scaffolds after 7 
days in bulk mineralization were 1.64 ± 0.11 and 1.71 ± 0.12, respectively. These 
values are similar to those of CaP deposits formed in the tooth model after 7 days 
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(Table 6.3). The Ca/P ratio of the crystals on CaMT scaffold was higher than those on 
CaC scaffold, probably because MTA in CaMT scaffold provided extra Ca as 





Figure 6.5 SEM images of the CaC (a,b) and CaMT (c,d) scaffolds after 7 days of 
mineralization in the tooth model (SBF-T) and bulk solution (SBF).  
 
The amount of CaP deposited on the CMCS scaffolds after 7-day mineralization in 
the tooth model and bulk can be related to the amount of P (quantified by ICP-MS) 
because both CaC and CaMT scaffolds contained no P prior to the mineralization. 
Although the Ca/P ratios suggest that the mineral deposits were HAP, the 
quantification results are reported as the amount of P, rather than HAP, since it has 
been reported that biological apatite is non-stoichiometric (Dorozhkin and Epple, 
2002; Tay et al., 2007). A similar approach was utilized by Kirkham et al. (2007). 
Figure 6.6 shows that significantly more P deposited on CaMT scaffold than CaC 
scaffold after 7 days. The increase in mineralization on CaMT scaffold can be 
attributed to the mineralization inducing capacity of MTA (Bozeman et al., 2006; Tay 
et al., 2007). The major constituents of MTA are tricalcium silicate (3CaO.SiO2), 
dicalcium silicate (2CaO.SiO2), tricalcium aluminate (3CaO.Al2O3), and calcium 
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sulphate (CaSO4.2H2O). The presence of silanol (SiOH) groups on the surface of 
MTA and the release of calcium hydroxide when MTA is hydrated have been 
suggested as the basis for MTA’s mineralization capability (Tay et al., 2007). 
Calcium hydroxide can also induce mineralization by providing calcium and 
hydroxide ions needed as building blocks for HAP formation (Tay et al., 2007). 
Figure 6.6 also shows that the mineralization in bulk SBF solution was significantly 
higher than that in the tooth model. This may be attributed to the limited contact 
between the scaffold and the mineralizing solution due to the diffusion barrier in the 
tooth model. Since tissue remnants have been removed during the preparation of the 
tooth model (Section 6.2.2), the diffusion barrier originated from the dentinal tubules 
and not from the cellular and proteinous components of the pulp. Under physiological 
condition, the diffusion barrier may be higher due to the presence of proteins and cells 
within the dentin structure. This can be verified in the future using in vivo animal 
model.  Relatively thick dentin remained under the cavities in the tooth model. Hence, 
the tooth model experiments represent the use of the scaffold in the case of a non-
exposed cavity. Since dentin permeability decreases as its thickness increases 
(Pashley, 1996), the use of thick but permeable dentin is beneficial to test the 
bioactivity of the scaffold under a high diffusion limitation. Since the scaffold was 
shown to be bioactive even when it is placed in a cavity with a thick dentin section, it 




Figure 6.6 Phosphorus content of CaC and CaMT scaffolds after 7 days of 
mineralization in bulk SBF (SBF) and the tooth model (SBF-T). * denotes significant 
differences in phosphorus content (P < 0.05) between CaMT and CaC scaffolds 
mineralized in the same system (bulk solution or the tooth model). # denotes 
significant differences (P < 0.05) in phosphorus content for the same type of scaffold 





Uncoated and MTA-coated CMCS scaffolds with high calcium chelating capacity 
were successfully synthesized in this study. These scaffolds are bioactive, as 
illustrated by their ability to induce biomineralization of HAP from simulated body 
fluid in a tooth model. The MTA coating significantly enhanced the bioactivity of the 
CMCS scaffold, resulting in ~66% increase in amount of induced HAP after 7 days 
when 1% w/w of MTA was applied. In terms of morphology, the HAP deposits were 
denser on MTA-coated scaffold as compared to those on the uncoated scaffold. Due 
to the diffusion barrier presented by the dentinal tubules in the tooth model, the 
amount of HAP formed in the tooth model was approximately one third of that 
formed in the bulk solution. This study demonstrates that MTA-coated CMCS 
scaffold, with its good bioactivity, is a promising material as a dentin mineralization 
patch. In addition, the tooth model was also shown to be a more representative in vitro 






7.1 Summary of major achievements 
Chitosan-based hydrogels, due to their numerous unique biological properties, have 
emerged as promising biomaterials for regenerative medicine. In this thesis, the 
intrinsic properties of the hydrogels were complimented with the bioactivity of 
bioactive agents to enhance the regenerative effects of the hydrogels on bone, wound, 
and tooth. 
 
Effective covalent immobilization of functional growth factors is a promising but 
challenging strategy in regenerative medicine. While the immobilization may provide 
better growth factor retention than the commonly used adsorption method, the growth 
factor functionality may be adversely affected by the immobilization procedure 
(Luginbuehl et al., 2004). Covalent immobilization of either BMP-2 or FGF-2 on 
chitosan films was investigated (Chapter 3) and the results indicate that the procedure 
successfully enhanced the biological activity of the films for potential bone and 
wound healing applications as compared to that of the pristine film. The 
immobilization was carried out using a relatively simple but effective method 
involving carbodiimide chemistry. With this method, control over the amount of 
immobilized growth factor can be readily achieved by adjusting the growth factor 
concentration in the loading solution. The bioactivity of the growth factor was not 
compromised following the immobilization. The growth factor loading efficiency was 
higher for the covalent immobilization than adsorption. The covalent immobilization 
also improved the functionality of the growth factors since the immobilized growth 
factors exhibit their activities for a longer period than adsorbed growth factors, due to 
substantially higher growth factor retention by covalent immobilization than 
adsorption. With these advantages, this study demonstrates the prospect of chitosan 
films with immobilized BMP-2 and FGF-2 as biomaterials to promote bone repair and 
wound healing, respectively. Prior to this study, a comparison of the bioactivity of 
immobilized growth factor and adsorbed growth factor on chitosan film using 
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different types of growth factor was not available. By providing a detailed analysis on 
the relationship between the growth factor release and bioactivity of films with 
adsorbed and immobilized growth factor, this study firmly established that growth 
factor retention is the main factor behind the superiority of the immobilized growth 
factor over adsorbed growth factor. 
 
The functionality of chitosan film as a growth factor carrier was further expanded via 
covalent co-immobilization of BMP-2 and VEGF (Chapter 4). Prior to this work, the 
interactions between co-immobilized BMP-2 and VEGF have not been documented 
elsewhere. The results in Chapter 4 show that the co-immobilized growth factors 
exhibited cross-activity, with the immobilized BMP-2 promoting ECFC functions and 
the immobilized VEGF stimulating osteoblast activity. In combination with the native 
osteogenic activity of the immobilized BMP-2 and angiogenic activity of the 
immobilized VEGF, this cross-activity enables the co-immobilized growth factors to 
promote osteoblast and ECFC functions in an additive fashion. This study highlights 
the possibility of simultaneous promotion of osteogenesis and vascularization using a 
covalent co-immobilization approach. It also clearly demonstrates the role and cross-
activity of the co-immobilized BMP-2 and VEGF. The successful enhancement of 
ECFC vascularization by the chitosan film with co-immobilized BMP-2 and VEGF is 
also important, since it further highlights the promise of this relatively unexplored 
type of cells for improving vascularization. 
 
Chitosan was grafted with carboxyl groups via carboxymethylation to improve its 
mineralization ability. The resultant material, CMCS, is a promising but relatively 
unexplored biomaterial for bone regeneration. The mineralization potential of CMCS 
was utilized to coat CMCS scaffolds with HAP (Chapter 5). It was found that HAP of 
distinct morphology was readily coated on the CMCS scaffolds via mineralization in 
different mineralizing solutions. The coatings substantially enhanced osteogenic 
differentiation of osteoblasts and BMSCs as compared to uncoated scaffolds. Prior to 
this study, responses of osteogenic cells to CMCS scaffold have not been evaluated. 
Similar level of enhancement was observed across the different coatings, indicating 
that the coating morphology plays no major role in the stimulations. These findings 




The mineralization ability of CMCS scaffold was further utilized for another 
prospective clinical application: remineralization of dentin layer of tooth affected by 
dental caries (Chapter 6). The possibility of using MTA to augment the mineralization 
ability of the CMCS scaffold was also investigated using a tooth model as well as 
bulk SBF solution. The use of a tooth model as a dental mineralization testing system 
is an advancement over the conventional method of using bulk solution. The use of 
MTA as a coating for inducing mineralization has also not been documented 
elsewhere. It was shown that the MTA coating complimented the induction of HAP 
formation by the CMCS, resulting in a higher amount of HAP formation on the MTA-
coated scaffold than on the non-coated scaffold. Less HAP was formed in the tooth 
model as compared to the bulk solution, indicating that the diffusion barrier presented 
by the tooth microstructure should be taken into account in dental mineralization tests.  
 
Overall, the work presented in this thesis demonstrates the feasibility and efficacy of 
covalently immobilized of growth factors on chitosan for expanding and improving 
the current applications of chitosan-based hydrogels in regenerative medicine. The 
selection and combination of growth factors for the covalent immobilization has been 
shown to be an important tool for optimizing the functionality of the hydrogels for 
regeneration of a target tissue. The work also highlights the efficacy of 
carboxymethylation to enhance the mineralization ability of chitosan and how this 
approach can be in used in CMCS hydrogels to promote bone and tooth regeneration. 
 
7.2 Suggestions for future work 
Based on the results of this thesis, the following studies are recommended for further 
expansion of the applications of chitosan-based hydrogels: 
1) As demonstrated in Chapters 3 and 4, chitosan-based hydrogels can be tailored 
for a particular application through the selection of growth factors to be 
immobilized on the hydrogels. This implies that more potential applications 
can be explored by immobilizing growth factors other than BMP-2, FGF-2, 
and VEGF. In the study of growth factor bioactivity, blocking antibody can 
also be used to verify the effect of the immobilized growth factor. It would 
also be interesting to conduct a comparative study on various covalent 
immobilization techniques for bioactive molecules on the hydrogels, as only 
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limited data is available on this aspect. The comparisons may shed light on the 
optimum immobilization technique that maximizes both the immobilization 
efficiency as well as the biological activity of the immobilized molecules.  
2) In this study, the growth factor was covalently immobilized on chitosan film 
without spacer using carbodiimide. The effect of spacer length can also be 
evaluated, by immobilizing spacer molecules of various lengths, such as 
dihydrazides (Sharon and Puleo, 2008), on chitosan prior to the 
immobilization of the growth factor. This investigation may provide 
information on the influence of the distance between the growth factor and the 
chitosan substrate on the bioactivity of the growth factor.  
3) Apart from the BMP-2 and VEGF combination described in Chapter 4, other 
growth factor combinations such as VEGF and FGF-2, or VEGF and Ang1 
may also be investigated to promote vascularization. In particular, 
immobilization of these growth factors on a porous chitosan scaffold may be 
useful in promoting vascularization on a three-dimensional scale. An 
alternative biomolecule that has a potential for promoting both osteogenesis 
and vascularization, such as sonic hedgehog, may also be used and compared 
to the dual growth factor combination. 
4) To reduce cost, peptide sequences of the active sites of growth factor may also 
be used instead of the full-length growth factor. Due to their substantially 
shorter peptide chain, the peptide sequences may be immobilized more 
efficiently than the full-length growth factor.  
5) The effects of different types of calcium phosphate coating on osteogenic cells 
are currently unclear. To shed light on this aspect, the HAP-coated CMCS 
scaffolds described in Chapter 5 can be compared to corresponding scaffolds 
coated with other types of calcium phosphate, such as octacalcium phosphate 
and β-tricalcium phosphate. Growth factors can also be added to the coatings 
to enhance the biological activity of the coated scaffolds since calcium 
phosphates have been reported to bind proteins including growth factors. This 
investigation may provide essential information on the interaction between the 
growth factor and different calcium phosphates and the corresponding 
bioactivity. This approach may also be extended for dental regeneration, by 
evaluating the influence of the scaffolds with and without the coatings and 
growth factors on the functions of dental cells, such as odontoblasts.  
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6) While the results in Chapter 6 show that CMCS scaffolds are a promising 
bioactive material, a study on CMCS scaffolds with varying porosity should 
also be conducted to investigate the optimum pore structure for bone grafting 
and dentin mineralization. For example, salt leaching and porogen gases can 
be used to control the porosity of the CMCS scaffolds. 
7) The potential of the hydrogels can be evaluated further in in vivo studies, 
which may provide crucial information on the hydrogel performance, such as 
their degradation and bioactivity, in situations resembling the actual 
physiological condition. More importantly, the in vivo setups can be used to 
test different applications previously envisioned in the in vitro studies, for 
example the use of the growth factor functionalized films as a wrap to promote 
bone healing and wound dressing, and the mineralized CMCS scaffolds as 
bone grafts. For the application of MTA-coated CMCS scaffold as a dentin 
remineralization patch, in vivo assay of the patch can be carried out to verify 
the effects of proteinous components of the pulp and cells, such as 
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